What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2024-04-15 compared with 2023-03-30 · 1241 added, 1443 removed, 628 unchanged (81% of the section changed)

11 unchanged sentences

Summary of Risk Factors

Our business is subject

to numerous risks and uncertainties that you should consider before investing in our company, as fully described below.

The principal

factors and uncertainties that make investing in our company risky include, among others:

Our business is subject to numerous risks and

uncertainties that you should consider before investing in our company, as fully described below.

The principal factors and uncertainties

that make investing in our company risky include, among others:

General Operating and Business Risks

limited operating history makes it difficult for us to evaluate our future business prospects

and make decisions based on those estimates of our future performance.

results of operations have not resulted in profitability and we may not be able to achieve

profitability going forward.

is substantial doubt about our ability to continue as a going concern, which will affect

our ability to obtain future financing and may require us to curtail our operations.

cash will only fund our operations for a limited time and we will need to raise additional

capital in order to support our development.

Laboratory Services MSO Acquisition will result in organizational changes that could create

significant growth for our business.

If we fail to effectively manage this growth and adapt

our business structure in a manner that preserves our reputation, then our business, financial

condition and results of operations could be harmed.

must effectively manage the growth of our operations, or our company will suffer.

prospects will suffer if we are not able to hire, train, motivate, manage, and retain a significant

number of highly skilled employees.

liability claims may adversely affect our business.

accordance with our strategic development policy, we may invest in companies for strategic

reasons and may not realize a return on our investments.

and maintaining patent protection depends on compliance with various procedural, document

submission, fee payment and other requirements imposed by governmental patent agencies, and

any patent protection we may obtain in the future could be reduced or eliminated for non-compliance

with these requirements.

is difficult and costly to protect our proprietary rights, and we may not be able to ensure

their protection.

If we fail to protect or enforce our intellectual property rights adequately

or secure rights to patents of others, the value of our intellectual property rights would

any of our trade secrets, know-how or other proprietary information is disclosed, the value

of our trade secrets, know-how and other proprietary rights would be significantly impaired

and our business and competitive position would suffer.

Our limited operating history makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance.

Our results of operations have not resulted in profitability and we may not be able to achieve profitability going forward.

There is substantial doubt about our ability to continue as a going concern, which will affect our ability to obtain future financing and may require us to curtail our operations.

Our cash will only fund our operations for a limited time and we will need to raise additional capital in order to support our development.

Joint ventures, joint ownership arrangements and other projects

pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated benefits associated

with such projects.

We must effectively manage the growth of our operations, or our company will suffer.

Our prospects will suffer if we are not able to hire, train, motivate, manage, and retain a significant number of highly skilled employees.

Potential liability claims may adversely affect our business.

In accordance with our strategic development policy, we may invest in companies for strategic reasons and may not realize a return on our investments.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and any patent protection we may obtain in the future could be reduced or eliminated for non-compliance with these requirements.

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual property rights adequately or secure rights to patents of others, the value of our intellectual property rights would diminish.

If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.

Risk Factors Related to our Laboratory Services

changes in healthcare reimbursement models and products, changes in government payment and

reimbursement systems, or changes in payer mix could have a material adverse effect on our

revenues, profitability and cash flow.

clinical testing business is highly competitive, and if we fail to provide an appropriately

priced level of service or otherwise fail to compete effectively it could have a material

adverse effect on our revenues and profitability.

to obtain and retain new customers, the loss of existing customers or material contracts,

or a reduction in services or tests ordered or specimens submitted by existing customers,

or the inability to retain existing and/or create new relationships with health systems could

impact our ability to successfully grow our business.

● Discontinuation

or recalls of existing testing products;

failure to develop or acquire licenses for new or

improved testing technologies;

or our customers using new technologies to perform their own

tests could adversely affect our business.

and increased consolidation of pharmaceutical, biotechnology and medical device companies,

health systems, physicians and other customers could adversely affect our business.

Continued changes in healthcare reimbursement models and products, changes in government payment and reimbursement systems, or changes in payer mix could have a material adverse effect on our revenues, profitability and cash flow.

The Laboratory Services MSO Acquisition will result in organizational changes that could create significant growth for our business.

If we fail to effectively manage this growth and adapt our business structure in a manner that preserves our reputation, then our business, financial condition and results of operations could be harmed.

The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability.

Failure to obtain and retain new customers, the loss of existing customers or material contracts, or a reduction in services or tests ordered or specimens submitted by existing customers, or the inability to retain existing and/or create new relationships with health systems could impact our ability to successfully grow our business.

Discontinuation or recalls of existing testing products;

failure to develop or acquire licenses for new or improved testing technologies;

or our customers using new technologies to perform their own tests could adversely affect our business.

Continued and increased consolidation of pharmaceutical, biotechnology and medical device companies, health systems, physicians and other customers could adversely affect our business.

Risk Factors Related to Clinical and Commercialization

may not be able to file INDs to commence additional clinical trials on the timelines we expect,

and even if we are able to do so, the FDA may not permit us to proceed.

have limited experience in conducting clinical trials.

in the commencement, enrollment, and completion of clinical testing could result in increased

costs to us and delay or limit our ability to obtain regulatory approval for our product

the results of earlier pre-clinical studies or clinical trials are not necessarily predictive

of future results, any product candidate we advance into clinical trials may not have favorable

results in later clinical trials or receive regulatory approval.

if our product candidates receive regulatory approval, we may still face future development

and regulatory difficulties.

cell based therapies we develop may become subject to unfavorable pricing regulations, third

party coverage and reimbursement practices or healthcare reform initiatives, thereby harming

our business.

We may not be able to file investigational new drug applications (INDs) to commence additional clinical trials on the timelines we expect, and even if we are able to do so, the FDA may not permit us to proceed.

We have limited experience in conducting clinical trials.

Delays in the commencement, enrollment, and completion of clinical testing could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates.

As the results of earlier pre-clinical studies or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.

Even if our product candidates receive regulatory approval, we may still face future development and regulatory difficulties.

Any cell based therapies we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business.

Risks Related to Our Securities

officers, directors and principal stockholders own a significant percentage of our capital

stock and will be able to exert significant control over matters that are subject to stockholder

we are unable to maintain listing of our securities on the Nasdaq Capital Market or another

reputable stock exchange, it may be more difficult for our stockholders to sell their securities.

price of our common stock may be volatile and fluctuate substantially, which could result

in substantial losses for our stockholders.

may experience dilution of your ownership interests because of the future issuance of additional

shares of our common or preferred stock or other securities that are convertible into or

exercisable for our common or preferred stock.

Our officers, directors and principal stockholders own a significant percentage of our capital stock and will be able to exert significant control over matters that are subject to stockholder approval.

If we are unable to maintain listing of our securities on The Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our stockholders to sell their securities.

The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.

You may experience dilution of your ownership interests because of the future issuance of additional shares of our common or preferred stock or other securities that are convertible into or exercisable for our common or preferred stock.

General Operating and Business Risks

14 unchanged sentences

in profitability and we may not be able to achieve profitability going forward.

We incurred net losses amounting to $11,930,847 and $9,090,499 for

the years ended December 31, 2022 and 2021, respectively.

As of December 31, 2022, we had an accumulated deficit of approximately $63.1

If we incur additional significant losses, our stock price may decline, perhaps significantly.

Our management is developing plans

to achieve profitability.

Our business plan is speculative and unproven.

There is no assurance that we will be successful in executing

our business plan or that even if we successfully implement our business plan, that we will be able to curtail our losses now or in the

Further, as we are a new enterprise, we expect that net losses will continue.

We incurred net losses amounting to

approximately $16.7 million and $11.9 million for the years ended December 31, 2023 and 2022, respectively.

As of December 31, 2023,

we had an accumulated deficit of approximately $79.8 million.

If we incur additional significant losses, our stock price may

decline, perhaps significantly.

Our management is developing plans to achieve profitability.

Our business plan is speculative and

There is no assurance that we will be successful in executing our business plan or that even if we successfully implement

our business plan, that we will be able to curtail our losses now or in the future.

Further, as we are a new enterprise, we expect

that net losses will continue.

There is substantial doubt about our ability

19 unchanged sentences

going concern.

At December 31, 2022, we had cash of approximately $2.0 million.

We will need to raise additional capital or generate

substantial revenue in order to support our development and commercialization efforts.

At December 31, 2023, we had cash of approximately $285,000.

We will need to raise additional capital or generate substantial

revenue in order to support our development and commercialization efforts.

If our available cash balances are insufficient

4 unchanged sentences

or for other reasons, including to:

development and expansion of our operations;

license or invest in technologies and additional laboratories;

or invest in complementary businesses or assets;

capital expenditures and general and administrative expenses.

fund development and expansion of our operations;

acquire, license or invest in technologies and additional laboratories;

acquire or invest in complementary businesses or assets;

finance capital expenditures and general and administrative expenses.

Our present and future funding requirements will

depend on many factors, including:

revenue growth rate and ability to generate cash flows from operating activities;

sales and marketing and research and development activities;

in regulatory oversight applicable to our products and services.

our revenue growth rate and ability to generate cash flows from operating activities;

our sales and marketing and research and development activities;

changes in regulatory oversight applicable to our products and services.

Other than our debt facility with our chairman,

we have no arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise

sufficient additional capital on acceptable terms, or at all, and if we are not successful in raising additional capital, we may not

be able to continue as a going concern.

We may seek additional capital through a combination of private and public equity offerings,

debt financings and strategic collaborations.

Debt financing, if obtained, may involve agreements that include covenants limiting or

restricting our ability to take specific actions, such as incurring additional debt, that could increase our expenses and require that

our assets secure such debt.

Equity financing, if obtained, could result in dilution to our then existing stockholders and/or require

such stockholders to waive certain rights and preferences.

If such financing is not available on satisfactory terms, or is not available

at all, we may be required to delay, scale back or eliminate the development of business opportunities and our operations and financial

condition may be materially adversely affected.

We can provide no assurances that any additional sources of financing will be available

to us on favorable terms, if at all.

Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse

effects on our operations.

If we raise additional capital by issuing

equity securities, our existing stockholders’ percentage ownership will be reduced and these stockholders may experience substantial

If we raise additional funds by issuing debt

securities, these debt securities would have rights senior to those of our Common Stock and the terms of the debt securities issued could

impose significant restrictions on our operations, including liens on our assets.

If we raise additional funds through collaborations

and licensing arrangements, we may be required to relinquish some rights to our technologies or products, or to grant licenses on terms

that are not favorable to us.

sufficient additional capital on acceptable terms, or at all, and if we are not successful in raising additional capital, we may not be

able to continue as a going concern.

We may seek additional capital through a combination of private and public equity offerings, debt

financings and strategic collaborations.

Debt financing, if obtained, may involve agreements that include covenants limiting or restricting

our ability to take specific actions, such as incurring additional debt, that could increase our expenses and require that our assets

secure such debt.

Equity financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders

to waive certain rights and preferences.

If such financing is not available on satisfactory terms, or is not available at all, we may

be required to delay, scale back or eliminate the development of business opportunities and our operations and financial condition may

be materially adversely affected.

We can provide no assurances that any additional sources of financing will be available to us on favorable

terms, if at all.

Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse effects on our

If we raise additional capital by issuing equity

securities, our existing stockholders’ percentage ownership will be reduced and these stockholders may experience substantial dilution.

If we raise additional funds by issuing debt securities,

these debt securities would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant

restrictions on our operations, including liens on our assets.

If we raise additional funds through collaborations and licensing arrangements,

we may be required to relinquish some rights to our technologies or products, or to grant licenses on terms that are not favorable to

We have significant outstanding debt obligations

and servicing these debt obligations will require a significant amount of capital, and our business may not be able to pay our substantial

As of December 31, 2022, we had $4.8 million

of outstanding indebtedness.

In order to service this indebtedness and any additional indebtedness we may incur in the future, we will

need to generate cash from our operating activities.

As of December 31, 2023, we had approximately

$9.1 million of outstanding indebtedness.

In order to service this indebtedness and any additional indebtedness we may incur in the future,

we will need to generate cash from our operating activities.

Our ability to generate cash is subject, in part, to our ability to successfully

execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control.

If we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, either when they mature,

or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may

negatively impact our business operations and financial condition.

we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, either when they mature, or

in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively

impact our business operations and financial condition.

If we breach any of the undertakings or default

2 unchanged sentences

indebtedness were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness.

Our business is subject

to risks arising from epidemic diseases, such as the outbreak of the COVID-19 illness.

The Coronavirus Disease 2019, or

COVID-19, pandemic which has been declared by the World Health Organization to be a “public health emergency of international

concern,” spread across the globe and impacted worldwide economic activity.

Although several vaccines have been developed,

a public health epidemic, including COVID-19, poses the risk that we or our employees, contractors, suppliers, and other partners

may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be

requested or mandated by governmental authorities.

While it is not possible at this time to estimate the full impact that future

pandemics, including COVID-19, could have on our business, the continued spread of COVID-19 and the measures taken by the

governments of countries affected could disrupt the supply chain and adversely impact our business, financial condition or results

of operations.

Future pandemics, including COVID-19, and mitigation measures may also have an adverse impact on global economic conditions which

could have an adverse effect on our business and financial condition.

The extent to which these pandemics impact our results

will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge

concerning the severity of the virus and the actions to contain its impact.

Our business and

operations may be further impacted by epidemics, outbreaks and other public health events.

Epidemics, outbreaks

or other public health events that are outside of our control could significantly disrupt our operations and adversely affect our financial

The global or national outbreak of an illness or other communicable disease, or any other public health crisis, such as COVID-19,

may cause disruptions to our business and operations, which may include (i) shortages of employees, (ii) unavailability of contractors

or subcontractors, (iii) interruption of supplies from third parties upon which we rely, (iv) recommendations of, or restrictions imposed

by government and health authorities, including quarantines, to address an outbreak and (v) restrictions that we and our contractors,

subcontractors and our customers impose, including facility shutdowns, to ensure the safety of employees.

We depend upon key personnel and need additional

Our success depends

on the continuing services of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola, our executive officers.

Our success depends on the continuing services

of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola, our executive officers.

The loss of Mr.

Ingargiola could have a material and adverse effect on our business operations.

Additionally,

the success of our operations will largely depend upon our ability to successfully attract and maintain competent and qualified key management

As with any company with limited resources, there can be no guaranty that we will be able to attract such individuals or that

the presence of such individuals will necessarily translate into profitability for us.

Our inability to attract and retain key personnel

may materially and adversely affect our business operations.

The supply of qualified technical, professional, managerial and other personnel,

including lab medical directors and lab operations managers, is currently constrained;

competition for qualified employees, even across

different industries, is intense, including as individuals leave the job market.

We may lose, or fail to attract and retain, key management

personnel, or qualified skilled technical, professional or other employees.

The same is true for patient-facing staff with specialized

training required to perform activities related to specimen collection.

In the future, if competition for the services of these professionals

increases, we may not be able to continue to attract and retain individuals in its markets.

Changes in key management, or the ability

to attract and retain qualified personnel, as a result of increased competition for talent, wage growth, or other market factors, could

lead to strategic and operational challenges and uncertainties, distractions of management from other key initiatives, and inefficiencies

and increased costs, any of which could adversely affect our business, financial condition, results of operations, and cash flows.

The Laboratory Services MSO Acquisition will

result in organizational changes that could create significant growth for our business.

If we fail to effectively manage this growth

and adapt our business structure in a manner that preserves our reputation, then our business, financial condition and results of operations

could be harmed.

On February 9, 2023, we acquired 40% of all the

issued and outstanding equity interests of Laboratory Services MSO.

The Laboratory Services MSO Acquisition has resulted in significant

growth in our operations.

We have incurred and will continue to incur significant expenditures and the allocation of management time

to assimilate Laboratory Services MSO in a manner that preserves the key aspects of our business, but there can be no assurance that

we will be successful in our efforts.

If we do not effectively integrate Laboratory Services MSO, the effectiveness of our business growth

could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results

of operations.

The success of our business will depend, in part,

on our ability to realize our anticipated benefits and opportunities from the acquisition.

We can provide no assurance that the anticipated

benefits of the Laboratory Services MSO Acquisition will be fully realized in the time frame anticipated or at all.

The failure to meet

the challenges involved in integrating the two businesses could cause an interruption of business activities, an increase in operating

costs or lower anticipated financial performance.

Our failure to achieve the anticipated and the potential benefits underlying our reasons

for the Laboratory Services MSO Acquisition could have a material adverse impact on our business, financial condition and results of

Additionally, the success of our operations

will largely depend upon our ability to successfully attract and maintain competent and qualified key management personnel.

company with limited resources, there can be no guaranty that we will be able to attract such individuals or that the presence of such

individuals will necessarily translate into profitability for us.

Our inability to attract and retain key personnel may materially and

adversely affect our business operations.

The supply of qualified technical, professional, managerial and other personnel, including lab

medical directors and lab operations managers, is currently constrained;

competition for qualified employees, even across different industries,

is intense, including as individuals leave the job market.

We may lose, or fail to attract and retain, key management personnel, or qualified

skilled technical, professional or other employees.

The same is true for patient-facing staff with specialized training required to perform

activities related to specimen collection.

In the future, if competition for the services of these professionals increases, we may not

be able to continue to attract and retain individuals in its markets.

Changes in key management, or the ability to attract and retain

qualified personnel, as a result of increased competition for talent, wage growth, or other market factors, could lead to strategic and

operational challenges and uncertainties, distractions of management from other key initiatives, and inefficiencies and increased costs,

any of which could adversely affect our business, financial condition, results of operations, and cash flows.

Joint ventures, joint ownership arrangements and other projects

pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated benefits associated

with such projects.

We are, and may be in the future, involved in

strategic joint ventures and other joint ownership arrangements.

We may not always be in complete alignment with our joint venture or

joint owner counterparties;

we may have differing strategic or commercial objectives and may be outvoted by our joint venture partners

or we may disagree on governance matters with respect to the joint venture entity or the jointly owned assets.

when we enter into joint ventures or joint ownership arrangements, we may be subject to a number of risks.

In some joint ventures and

joint ownership arrangements we may not be responsible for the operation of projects and will rely on our joint venture or

joint owner counterparties for such services.

Joint ventures and joint ownership arrangements may also require us to expend additional

internal resources that could otherwise be directed to other projects.

If we are unable to successfully execute and manage our existing

and any proposed joint venture and joint owner arrangements, it could adversely impact our financial and operating results.

We may be undertaking, or participating with various

counterparties in, a number of projects that involve forming joint ventures and acquiring laboratories that are accretive to our commercial

Many of these projects could involve numerous regulatory, environmental, commercial, economic, political and legal uncertainties

that are beyond our control, including the following:

● We may be unable to realize our forecasted commercial, operational or administrative synergies in

connection with our joint venture and joint ownership arrangements, including the Laboratory Services MSO Acquisition;

● Joint ventures and other joint ownership arrangements may demand substantial internal resources and may

divert resources and attention from other areas of our business.

As a result of these uncertainties, the anticipated benefits associated

with our joint ventures and joint ownership arrangements may not be achieved or could be delayed.

In turn, this could negatively impact

our cash flow and our ability to make or increase cash distributions to our partners.

We must effectively manage the growth of our

9 unchanged sentences

the demands of our growing business.

Any failure by our management to effectively anticipate, implement, and manage changes required

to sustain our growth would have a material adverse effect on our business, financial condition, and results of operations.

Any failure by our management to effectively anticipate, implement, and manage changes required to

sustain our growth would have a material adverse effect on our business, financial condition, and results of operations.

Our revenue and results of operations may

suffer if we are unable to attract new clients, continue to engage existing clients, or sell additional products and services.

We presently derive our revenue from providing

medical related consulting services to related parties and generating rental revenue from our income-producing real estate property in

Our growth therefore depends on our ability to attract new clients, maintain existing clients and properties and sell additional

products and services to existing clients.

This depends on our ability to understand and anticipate market and pricing trends and our

clients’ needs and our ability to deliver consistent, reliable, high-quality services.

Our failure to engage new clients, continue

to re-engage with our existing clients or cross-sell additional services could materially and adversely affect our operating results.

suffer if we are unable to attract new tenants.

We presently derive our revenue from rental revenue from our income-producing

real estate property in New Jersey.

Our growth therefore depends on our ability to attract new tenants.

This depends on our ability to

understand and anticipate market and pricing trends and our tenants’ needs.

Our failure to attract new tenants could materially

and adversely affect our operating results.

Our prospects will suffer if we are not able

5 unchanged sentences

which we have provided consulting services.

Our future success depends upon our ability to hire, train, motivate, manage, and retain

a significant number of highly skilled employees, particularly research analysts, technical experts, and sales and marketing staff.

will experience competition for professional personnel in each of our business lines.

Our future success depends upon our ability to hire, train, motivate, manage, and retain a

significant number of highly skilled employees, particularly research analysts, technical experts, and sales and marketing staff.

experience competition for professional personnel in each of our business lines.

Hiring, training, motivating, managing, and retaining

9 unchanged sentences

of regulatory scrutiny and litigation, and we also may become the subject of such litigation based on our advice and services.

litigation, whether or not resulting in a judgment against us, may adversely affect our reputation and could have a material adverse

effect on our financial condition and results of operations.

litigation, whether or not resulting in a judgment against us, may adversely affect our reputation and could have a material adverse effect

on our financial condition and results of operations.

We may not have adequate insurance coverage for claims against us.

1 unchanged sentence

policy, we may invest in companies for strategic reasons and may not realize a return on our investments.

From time to time, we may make investments in

These investments may be for strategic objectives to support our key business initiatives but may also be standalone investments

or acquisitions.

Such investments or acquisitions could include equity or debt instruments in private companies, many of which may not

be marketable at the time of our initial investment.

These companies may range from early-stage companies that are often still defining

their strategic direction to more mature companies with established revenue streams and business models.

The success of these companies

may depend on product development, market acceptance, operational efficiency, and other key business factors.

The companies in which

we invest may fail because they may not be able to secure additional funding, obtain favorable investment terms for future financings,

or take advantage of liquidity events such as public offerings, mergers, and private sales.

If any of these private companies fails,

we could lose all or part of our investment in that company.

If we determine that impairment indicators exist and that there are other-than-temporary

declines in the fair value of the investments, we may be required to write down the investments to their fair value and recognize the

related write-down as an investment loss.

From time to time, we may make investments in companies.

These investments

may be for strategic objectives to support our key business initiatives but may also be standalone investments or acquisitions.

Such investments

or acquisitions could include equity or debt instruments in private companies, many of which may not be marketable at the time of our

initial investment.

These companies may range from early-stage companies that are often still defining their strategic direction to more

mature companies with established revenue streams and business models.

The success of these companies may depend on product development,

market acceptance, operational efficiency, and other key business factors.

The companies in which we invest may fail because they may

not be able to secure additional funding, obtain favorable investment terms for future financings, or take advantage of liquidity events

such as public offerings, mergers, and private sales.

If any of these private companies fails, we could lose all or part of our investment

in that company.

If we determine that impairment indicators exist and that there are other-than-temporary declines in the fair value of

the investments, we may be required to write down the investments to their fair value and recognize the related write-down as an investment

For the year ended December 31, 2023, we had an impairment of goodwill acquired from Lab Services MSO acquisition of approximately

$9.2 million.

In the future, we could have additional impairment charges related to investments that we may make.

We face intense competition which could cause us to lose market

6 unchanged sentences

pricing, licensing, distribution, or marketing to develop a market position.

If we fail to comply with our obligations

in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business

If we fail to comply with our obligations in

the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business

relationships with our licensors, we could lose intellectual property rights that are important to our business.

6 unchanged sentences

or any other product candidates we may identify and pursue.

Avalon GloboCare and Arbele Limited (“Arbele”)

are parties to the joint venture Avactis Biosciences, Inc.

(“Avactis”) for development of AVA-011, a mRNA-based dual anti-CD19-CD22

CAR-T cell therapy candidate.

Arbele has granted Avactis an exclusive license to its rights in this technology.

We and Arbele may need

to obtain additional licenses from others to advance our research and development activities or allow the commercialization of mRNA-based

CAR technology or any other product candidates we may identify and pursue.

The Company formed a strategic partnership with

HydroPeptide, LLC, a leading epigenetics skin care company, to engage in co-development and commercialization of a series of clinical-grade,

exosome-based cosmeceutical and orthopedic products.

As part of this agreement, the Company signed a three-way Material Transfer Agreement

between Avalon GloboCare, HydroPeptide and the University of Pittsburgh Medical Center.

The Company and the University of Pittsburgh

of the Commonwealth System of Higher Education (the “University”) entered into a Corporate Research Agreement (the “University

Pursuant to the University Agreement, for a term of two years the University agreed to use its reasonable efforts

to perform academic research funded by the Company in connection with the development of point-of-care modular autonomous processing

system to generate clinical-grade AVA-011, a RNA-based chimeric antigen receptor (CAR) T-cell therapy candidate (the “Project”)

subject to the appointment of Dr.

Yen Michael S.

Hsu as Principal Investigator.

Our agreements with MIT, Hydropeptide, University

of Pittsburg and Arbele impose, and we expect that future agreements will impose, various development, diligence, commercialization,

or other obligations on AVAR and us.

In spite of our efforts, these partners may conclude that we have materially breached its obligations

under such agreements and might therefore terminate the agreements, thereby removing or limiting our ability or our subsidiary AVAR’s

ability to develop and commercialize products and technology covered by these license agreements.

If these in-licenses are terminated,

or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek

regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization

of CAR or exosome technology or other product candidates that we may identify.

Any of the foregoing could have a material adverse effect

on our competitive position, business, financial conditions, results of operations, and prospects.

Moreover, disputes may arise regarding intellectual

property subject to a licensing agreement, including:

scope of rights granted under the license agreement and other interpretation-related issues;

extent to which our product candidates, technology and processes infringe on intellectual

property of the licensor that is not subject to the licensing agreement;

sublicensing of patent and other rights under our collaborative development relationships;

diligence obligations under the license agreement and what activities satisfy those diligence

inventorship and ownership of inventions and know-how resulting from the joint creation or

use of intellectual property by our licensors and us and our partners;

priority of invention of patented technology.

● the scope of rights granted

under the license agreement and other interpretation-related issues;

● the extent to which our product

candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

● the sublicensing of patent

and other rights under our collaborative development relationships;

● our diligence obligations under

the license agreement and what activities satisfy those diligence obligations;

● the inventorship and ownership

of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;

● the priority of invention of

patented technology.

In addition, the agreements under which we currently

3 unchanged sentences

be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other

obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition,

results of operations, and prospects.

Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability

to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize

obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results

of operations, and prospects.

Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to

maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize

the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations,

and prospects.

We may face uncertainty and difficulty in

obtaining and enforcing our patents and other proprietary rights.

We may face uncertainty and difficulty in obtaining

and enforcing our patents and other proprietary rights.

There can be no assurance that any patent applications

8 unchanged sentences

or alternative product candidates in a non-infringing manner.

The cost of litigation to uphold the validity and prevent infringement

of a patent is substantial.

Furthermore, there can be no assurance that others will not independently develop substantially equivalent

technologies not covered by patents to which we have rights or obtain access to our know-how.

In addition, the laws of certain countries

may not adequately protect our intellectual property.

Our competitors may possess or obtain patents on products or processes that are

necessary or useful to the development, use, or manufacture of our product candidates.

There can also be no assurance that our proposed

technology will not infringe upon patents or proprietary rights owned by others, with the result that others may bring infringement claims

against us and require us to license such proprietary rights, which may not be available on commercially reasonable terms, if at all.

Any such litigation, if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management

resources, and injunction against continued manufacture, use, or sale of certain products or processes.

The cost of litigation to uphold the validity and prevent infringement of

a patent is substantial.

Furthermore, there can be no assurance that others will not independently develop substantially equivalent technologies

not covered by patents to which we have rights or obtain access to our know-how.

In addition, the laws of certain countries may not adequately

protect our intellectual property.

Our competitors may possess or obtain patents on products or processes that are necessary or useful

to the development, use, or manufacture of our product candidates.

There can also be no assurance that our proposed technology will not

infringe upon patents or proprietary rights owned by others, with the result that others may bring infringement claims against us and

require us to license such proprietary rights, which may not be available on commercially reasonable terms, if at all.

Any such litigation,

if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management resources, and

injunction against continued manufacture, use, or sale of certain products or processes.

We rely upon non-patented proprietary know-how.

1 unchanged sentence

independently develop substantially equivalent proprietary information or techniques or gain access to our proprietary know-how.

of the foregoing events could have a material adverse effect on us.

the foregoing events could have a material adverse effect on us.

In addition, if any of our trade secrets, know-how or other proprietary

information were to be disclosed, or misappropriated, the value of our trade secrets, know-how and other proprietary rights would be

significantly impaired and our business and competitive position would suffer.

information were to be disclosed, or misappropriated, the value of our trade secrets, know-how and other proprietary rights would be significantly

impaired and our business and competitive position would suffer.

In September 2011, the Leahy-Smith America Invents

6 unchanged sentences

Third parties are allowed to submit prior art before the issuance of a patent

Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, post-grant and inter partes

review, or interference proceedings challenging our patent rights.

An adverse determination in any such submission, proceeding or

litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.

Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, post-grant and inter partes review,

or interference proceedings challenging our patent rights.

An adverse determination in any such submission, proceeding or litigation could

reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.

The USPTO has developed new and untested regulations

2 unchanged sentences

The Leahy-Smith

Act has also introduced procedures that may make it easier for third parties to challenge issued patents, as well as to intervene in

the prosecution of patent applications.

Finally, the Leahy-Smith Act contains new statutory provisions that still require the USPTO to

issue new regulations for their implementation, and it may take the courts years to interpret the provisions of the new statute.

Act has also introduced procedures that may make it easier for third parties to challenge issued patents, as well as to intervene in the

prosecution of patent applications.

Finally, the Leahy-Smith Act contains new statutory provisions that still require the USPTO to issue

new regulations for their implementation, and it may take the courts years to interpret the provisions of the new statute.

it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.

4 unchanged sentences

property rights throughout the world.

Filing, prosecuting and defending patents on

our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in

some countries outside the United States may be less extensive than those in the United States.

In addition, the laws of some foreign

countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.

Consequently,

we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling

or importing products made using our inventions in and into the United States or other jurisdictions.

Competitors may use our technologies

in jurisdictions where we do not obtain patent protection to develop their own products and may also export infringing products to territories

where we have patent protection, but enforcement is not as strong as that in the United States.

These products may compete with our products

and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Filing, prosecuting and defending patents on our

product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some

countries outside the United States may be less extensive than those in the United States.

In addition, the laws of some foreign countries

do not protect intellectual property rights to the same extent as federal and state laws in the United States.

Consequently, we may not

be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing

products made using our inventions in and into the United States or other jurisdictions.

Competitors may use our technologies in jurisdictions

where we do not obtain patent protection to develop their own products and may also export infringing products to territories where we

have patent protection, but enforcement is not as strong as that in the United States.

These products may compete with our products and

our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems

10 unchanged sentences

awarded, if any, may not be commercially meaningful.

Accordingly, our efforts to enforce our intellectual property rights around the

world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Patent terms may be inadequate to protect

our competitive position on our product candidates for an adequate amount of time.

Accordingly, our efforts to enforce our intellectual property rights around the world

may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Patent terms may be inadequate to protect our

competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan.

8 unchanged sentences

candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.

any patents we may obtain may not provide us with sufficient rights to exclude others from commercializing products similar or identical

As a result, any

patents we may obtain may not provide us with sufficient rights to exclude others from commercializing products similar or identical to

Obtaining and maintaining patent protection

2 unchanged sentences

Periodic maintenance fees, renewal fees, annuity

fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental

patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.

The USPTO and various

governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions

during the patent application process.

There are situations in which non-compliance can result in abandonment or lapse of the patent

or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

In such an event, our competitors

might be able to enter the market and this circumstance would have a material adverse effect on our business.

It is difficult and costly to protect our

proprietary rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual property rights

adequately or secure rights to patents of others, the value of our intellectual property rights would diminish.

Our commercial viability will depend in part

on obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used to manufacture

fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent

agencies outside of the United States in several stages over the lifetime of the patents and/or applications.

The USPTO and various non-U.S.

governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during

the patent application process.

There are situations in which non-compliance can result in abandonment or lapse of the patent or patent

application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

In such an event, our competitors might

be able to enter the market and this circumstance would have a material adverse effect on our business.

It is difficult and costly to protect our proprietary

rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual property rights adequately

or secure rights to patents of others, the value of our intellectual property rights would diminish.

Our commercial viability will depend in part on

obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used to manufacture

them, as well as successfully defending these patents against third-party challenges.

Our ability to stop third parties from making,

using, selling, offering to sell, or importing our products is dependent upon the extent to which we obtain rights under valid and enforceable

Our ability to stop third parties from making, using,

selling, offering to sell, or importing our products is dependent upon the extent to which we obtain rights under valid and enforceable

patents or trade secrets that cover these activities.

12 unchanged sentences

or keep our competitive advantage.

may be able to make products that are similar to our product candidates but that are not

covered by the claims of any patents;

might not have been the first to make the inventions covered by any issued patents or patent

applications;

might not have been the first to file patent applications for these inventions;

is possible that any patent applications we own or license will not result in issued patents;

issued patents may not provide us with any competitive advantages, or may be held invalid

or unenforceable as a result of legal challenges by third parties;

may not develop additional proprietary technologies that are patentable or protectable under

trade secrets law;

patents of others may have an adverse effect on our business.

We also may rely on trade secrets to protect

our technology, especially where we do not believe patent protection is appropriate or obtainable.

However, trade secrets are difficult

● others may be able to make

products that are similar to our product candidates but that are not covered by the claims of any patents;

● we might not have been the

first to make the inventions covered by any issued patents or patent applications;

● we might not have been the

first to file patent applications for these inventions;

● it is possible that any patent

applications we own or license will not result in issued patents;

● any issued patents may not

provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;

● we may not develop additional

proprietary technologies that are patentable or protectable under trade secrets law;

● the patents of others may have

an adverse effect on our business.

We also may rely on trade secrets to protect our

technology, especially where we do not believe patent protection is appropriate or obtainable.

However, trade secrets are difficult to

Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific

6 unchanged sentences

inventorship of patents and other intellectual property.

We or our licensors may be subject to claims

that former employees, collaborators or other third parties have an interest as an inventor or co-inventor in intellectual property we

own or license.

We or our licensors may be subject to claims that

former employees, collaborators or other third parties have an interest as an inventor or co-inventor in intellectual property we own

For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants

4 unchanged sentences

of our owned or in-licensed patents, trade secrets or other intellectual property.

If we or our licensors fail in defending any such

claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or

right to use, intellectual property that is important to our product candidates.

Even if we are successful in defending against such

claims, litigation could result in substantial costs and be a distraction to management and other employees.

Any of the foregoing could

have a material adverse effect on our business, financial condition, results of operations and prospects.

If we or our licensors fail in defending any such claims,

in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to

use, intellectual property that is important to our product candidates.

Even if we are successful in defending against such claims, litigation

could result in substantial costs and be a distraction to management and other employees.

Any of the foregoing could have a material adverse

effect on our business, financial condition, results of operations and prospects.

If any of our trade secrets, know-how or other

3 unchanged sentences

and experience of our scientific and technical personnel, and our consultants and advisors.

To help protect our proprietary know-how

and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality

To this end, we require all of our employees, consultants, advisors and contractors to enter into agreements which prohibit

unauthorized disclosure and use of confidential information and, where applicable, require disclosure and assignment to us of the ideas,

developments, discoveries and inventions important to our business.

These agreements are often limited in duration and may not provide

adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure

or the lawful development by others of such information.

There is no assurance that such agreements will be honored by such parties or

enforced in whole or part by the courts.

We cannot be certain that others will not gain access to these trade secrets or that our patents

will provide adequate protection.

Others may independently develop substantially equivalent proprietary information and techniques or

otherwise gain access to our trade secrets.

In addition, enforcing a claim that a third party illegally obtained and is using any of

our trade secrets is expensive and time consuming, and the outcome is unpredictable.

If any of our trade secrets, know-how or other proprietary

information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired

and our business and competitive position would suffer.

To help protect our proprietary know-how and

our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality agreements.

To this end, we require all of our employees, consultants, advisors and contractors to enter into agreements which prohibit unauthorized

disclosure and use of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments,

discoveries and inventions important to our business.

These agreements are often limited in duration and may not provide adequate protection

for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development

by others of such information.

There is no assurance that such agreements will be honored by such parties or enforced in whole or part

by the courts.

We cannot be certain that others will not gain access to these trade secrets or that our patents will provide adequate

Others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access

to our trade secrets.

In addition, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive

and time consuming, and the outcome is unpredictable.

If any of our trade secrets, know-how or other proprietary information is improperly

disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and

competitive position would suffer.

We may incur substantial costs as a result

6 unchanged sentences

even if we were successful in discontinuing the infringement of our patents.

In addition, there is a risk that the court will decide

that these patents are not valid and that we do not have the right to stop the other party from using the inventions.

There is also the

risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other

party’s activities do not infringe our rights to these patents.

In addition, there is a risk that the court will decide that

these patents are not valid and that we do not have the right to stop the other party from using the inventions.

There is also the risk

that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other party’s

activities do not infringe our rights to these patents.

In addition, the U.S.

Supreme Court has in the past invalidated

tests used by the USPTO in granting patents over the past 20 years.

As a consequence, issued patents may be found to contain invalid

claims according to the newly revised standards.

Some of our own patents may be subject to challenge and subsequent invalidation in a

variety of post-grant proceedings, particularly inter partes review, before the USPTO or during litigation under the revised criteria,

which make it more difficult to defend the validity of claims in already issued patents.

Furthermore, a third party may claim that we

or our manufacturing or commercialization partners are using inventions covered by the third party’s patent rights and may go to

court to stop us from engaging in our normal operations and activities, including making or selling our product candidates.

These lawsuits

are costly and could affect our results of operations and divert the attention of managerial and technical personnel.

There is a risk

that a court could decide that we or our commercialization partners are infringing the third party’s patents and order us or our

partners to stop the activities covered by the patents.

In addition, there is a risk that a court could order us or our partners to pay

the other party damages for having violated the other party’s patents.

The biotechnology industry has produced a proliferation

of patents, and it is not always clear to industry participants, including us, which patents cover various types of products, manufacturing

processes or methods of use.

The coverage of patents is subject to interpretation by the courts, and the interpretation is not always

If we are sued for patent infringement, we would need to demonstrate that our products, manufacturing processes or methods of

use either do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not be able

Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome

the presumption of validity enjoyed by issued patents.

Supreme Court has in the past invalidated tests used by

the USPTO in granting patents over the past 20 years.

As a consequence, issued patents may be found to contain invalid claims according

to the newly revised standards.

Some of our own patents may be subject to challenge and subsequent invalidation in a variety of post-grant

proceedings, particularly inter partes review, before the USPTO or during litigation under the revised criteria, which make it

more difficult to defend the validity of claims in already issued patents.

Furthermore, a third party may claim that we or

our manufacturing or commercialization partners are using inventions covered by the third party’s patent rights and may go to court

to stop us from engaging in our normal operations and activities, including making or selling our product candidates.

These lawsuits are

costly and could affect our results of operations and divert the attention of managerial and technical personnel.

There is a risk that

a court could decide that we or our commercialization partners are infringing the third party’s patents and order us or our partners

to stop the activities covered by the patents.

In addition, there is a risk that a court could order us or our partners to pay the other

party damages for having violated the other party’s patents.

The biotechnology industry has produced a proliferation of patents,

and it is not always clear to industry participants, including us, which patents cover various types of products, manufacturing processes

or methods of use.

The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.

we are sued for patent infringement, we would need to demonstrate that our products, manufacturing processes or methods of use either

do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not be able to do this.

Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome the presumption

of validity enjoyed by issued patents.

As some patent applications in the United States

1 unchanged sentence

are typically not published until eighteen months after filing, and because publications in the scientific literature often lag behind

actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents

or our pending applications, or that we were the first to invent the technology.

Our competitors may have filed, and may in the future

file, patent applications covering technology similar to ours.

Any such patent applications may have priority over our patent applications

or patents, which could further require us to obtain rights to issued patents covering such technologies.

If another party has filed

a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by

the USPTO to determine priority of invention in the United States.

The costs of these proceedings could be substantial, and it is possible

that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention

prior to our own invention, resulting in a loss of our U.S.

actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or

our pending applications, or that we were the first to invent the technology.

Our competitors may have filed, and may in the future file,

patent applications covering technology similar to ours.

Any such patent applications may have priority over our patent applications or

patents, which could further require us to obtain rights to issued patents covering such technologies.

If another party has filed a United

States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO

to determine priority of invention in the United States.

The costs of these proceedings could be substantial, and it is possible that

such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior

to our own invention, resulting in a loss of our U.S.

patent position with respect to such inventions.

7 unchanged sentences

Freedom of Information Act.

though we believe our information would be excluded from the scope of such statutes, there are no assurances that we can protect our

confidential information from being disclosed under the provisions of such laws.

If any confidential or proprietary information is released

to the public, such disclosures may negatively impact our ability to protect our intellectual property rights.

though we believe our information would be excluded from the scope of such statutes, there are no assurances that we can protect our confidential

information from being disclosed under the provisions of such laws.

If any confidential or proprietary information is released to the

public, such disclosures may negatively impact our ability to protect our intellectual property rights.

Breaches or compromises of our information

security systems or our information technology systems or infrastructure could result in exposure of private information, disruption

of our business and damage to our reputation, which could harm our business, results of operation and financial condition.

security systems or our information technology systems or infrastructure could result in exposure of private information, disruption of

our business and damage to our reputation, which could harm our business, results of operation and financial condition.

We utilize information security and information

2 unchanged sentences

A security breach of our network,

hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation and potential

Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on

companies within the healthcare industry.

Although we believe that we take appropriate measures to safeguard sensitive information within

our possession, we may not have the resources or technical sophistication to anticipate or prevent rapidly-evolving types of cyber-attacks

targeted at us, our clients, our patients, or others who have entrusted us with information.

Actual or anticipated attacks may cause

us to incur costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party

experts and consultants.

hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation and potential liability.

Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies

within the healthcare industry.

Although we believe that we take appropriate measures to safeguard sensitive information within our possession,

we may not have the resources or technical sophistication to anticipate or prevent rapidly-evolving types of cyber-attacks targeted at

us, our clients, our patients, or others who have entrusted us with information.

Actual or anticipated attacks may cause us to incur costs,

including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.

We invest in industry standard security technology to protect personal information.

Advances in computer capabilities,

new technological discoveries, or other developments may result in the technology used by us to protect personal information or other

data being breached or compromised.

Advances in computer capabilities, new technological

discoveries, or other developments may result in the technology used by us to protect personal information or other data being breached

or compromised.

To our knowledge, we have not experienced any material breach of our cybersecurity systems.

or our third-party service provider systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems

with transitioning to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could

occur as a result of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts

of terrorism, circumvention of security systems, or other cyber-attacks, we could experience delays or decreases in revenue, and reduced

efficiency of our operations.

Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss,

misappropriation or corruption of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory

actions, sanctions or other statutory penalties, any or all of which could adversely affect our business, and cause us to incur significant

losses and remediation costs.

If our or our third-party

service provider systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning

to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could occur as a result

of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts of terrorism, circumvention

of security systems, or other cyber-attacks, we could experience delays or decreases in revenue, and reduced efficiency of our operations.

Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss, misappropriation or corruption

of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory actions, sanctions or other

statutory penalties, any or all of which could adversely affect our business, and cause us to incur significant losses and remediation

We may be exposed to liabilities under the

7 unchanged sentences

and agreements with third parties where corruption may occur.

It is our policy to implement safeguards to prevent these practices by

our employees.

It is our policy to implement safeguards to prevent these practices by our

However, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants,

1 unchanged sentence

Violations of the FCPA or other anti-corruption

laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our

business, operating results and financial condition.

In addition, the United States government may seek to hold our company liable for

successor liability FCPA violations committed by companies in which we invest or that we acquire.

Risk Factors Related to our Laboratory Services

Continued changes

in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems,

or changes in payer mix, including an increase in third-party benefits management and value-based payment models, could have a material

adverse effect on our revenues, profitability and cash flow.

laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business,

operating results and financial condition.

In addition, the United States government may seek to hold our company liable for successor

liability FCPA violations committed by companies in which we invest or that we acquire.

Risk Factors Related to our Lab Services MSO

Continued changes in healthcare reimbursement

models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix,

including an increase in third-party benefits management and value-based payment models, could have a material adverse effect on our revenues,

profitability and cash flow.

Diagnostic testing services are billed to managed

1 unchanged sentence

services are billed to a party other than the physician or other authorized person who ordered the test.

Increases in the percentage

of services billed to government and MCOs could have an adverse effect on our revenues.

Increases in the percentage of

services billed to government and MCOs could have an adverse effect on our revenues.

Although we currently do not provide any “in

4 unchanged sentences

and engage in direct negotiation of rates.

Other MCOs adopt broader networks with generally uniform fee structures for participating

clinical laboratories.

In some cases, those fee structures are specific to independent clinical laboratories, while the fees paid to

hospital-based and physician-office laboratories may be different, and are typically higher.

MCOs may also offer Managed Medicare or

Managed Medicaid plans.

In addition, an increasing number of MCOs are implementing, directly or through third parties, various types

of laboratory benefit management programs that may include laboratory networks, utilization management tools (such as prior authorization

and/or prior notification), and claims edits, which may impact coverage or reimbursement for commercial laboratory tests.

Some of these

programs address commercial laboratory testing broadly, while others are focused on certain types of testing such as molecular, genetic

and toxicology testing.

An increase in the use of such programs could lead to increased denial of claims, extended appeals, and reduced

Other MCOs adopt broader networks with generally uniform fee structures for participating clinical

laboratories.

In some cases, those fee structures are specific to independent clinical laboratories, while the fees paid to hospital-based

and physician-office laboratories may be different, and are typically higher.

MCOs may also offer Managed Medicare or Managed Medicaid

In addition, an increasing number of MCOs are implementing, directly or through third parties, various types of laboratory benefit

management programs that may include laboratory networks, utilization management tools (such as prior authorization and/or prior notification),

and claims edits, which may impact coverage or reimbursement for commercial laboratory tests.

Some of these programs address commercial

laboratory testing broadly, while others are focused on certain types of testing such as molecular, genetic and toxicology testing.

increase in the use of such programs could lead to increased denial of claims, extended appeals, and reduced revenue.

Our ability to attract and retain MCOs is critical

10 unchanged sentences

Measures to regulate healthcare delivery in general, and clinical laboratories in particular, have resulted in reduced prices,

added costs and decreased test utilization for the commercial laboratory industry by increasing complexity and adding new regulatory

and administrative requirements.

added costs and decreased test utilization for the commercial laboratory industry by increasing complexity and adding new regulatory and

administrative requirements.

Pursuant to legislation passed in late 2003, the percentage of Medicare beneficiaries enrolled in Managed

8 unchanged sentences

If our laboratory services

business cannot offset additional reductions in the payments it receives for its services by reducing costs, increasing test volume,

and/or introducing new services and procedures, it could have a material adverse effect on our revenues, profitability and cash flows.

In 2014, Congress passed the Protecting Access to Medicare Act (PAMA), requiring Medicare to change the way payment rates are calculated

for tests paid under the Clinical Laboratory Fee Schedule (CLFS), and to base the payment on the weighted median of rates paid by private

On June 23, 2016, CMS issued a final rule to implement PAMA that required applicable laboratories, including our laboratory services

business, to begin reporting their test-specific private payer payment amounts to CMS during the first quarter of 2017.

CMS exercised

enforcement discretion to permit reporting for an additional 60 days, through May 30, 2017.

CMS used that private market data to calculate

weighted median prices for each test (based on applicable current procedural technology (CPT) codes) to represent the new CLFS rates

beginning in 2018, subject to certain phase-in limits.

business cannot offset additional reductions in the payments it receives for its services by reducing costs, increasing test volume, and/or

introducing new services and procedures, it could have a material adverse effect on our revenues, profitability and cash flows.

Congress passed the Protecting Access to Medicare Act (PAMA), requiring Medicare to change the way payment rates are calculated for tests

paid under the Clinical Laboratory Fee Schedule (CLFS), and to base the payment on the weighted median of rates paid by private payers.

On June 23, 2016, CMS issued a final rule to implement PAMA that required applicable laboratories, including our laboratory services business,

to begin reporting their test-specific private payer payment amounts to CMS during the first quarter of 2017.

CMS exercised enforcement

discretion to permit reporting for an additional 60 days, through May 30, 2017.

CMS used that private market data to calculate weighted

median prices for each test (based on applicable current procedural technology (CPT) codes) to represent the new CLFS rates beginning

in 2018, subject to certain phase-in limits.

For 2018-2020, a test price could not be reduced by more than 10% per year.

a result of provisions included within the CARES Act, PAMA rate reductions for 2021 were suspended.

As a result of the Protecting Medicare

and American Farmers from Sequester Cuts Act that became law in December 2021, the data reporting requirements and Medicare reimbursement

cuts that would have occurred under PAMA in 2022 were delayed by one additional year.

As a result of the Consolidated Appropriations

Act, 2023, which became law in December 2022, the data reporting requirements and Medicare reimbursement cuts that would have occurred

under PAMA in 2023 were delayed by one additional year.

As a result of

provisions included within the CARES Act, PAMA rate reductions for 2021 were suspended.

As a result of the Protecting Medicare and American

Farmers from Sequester Cuts Act that became law in December 2021, the data reporting requirements and Medicare reimbursement cuts that

would have occurred under PAMA in 2022 were delayed by one additional year.

As a result of the Consolidated Appropriations Act, 2023,

which became law in December 2022, the data reporting requirements and Medicare reimbursement cuts that would have occurred under PAMA

in 2023 were delayed by one additional year.

For 2024-2026, a test price cannot be reduced

5 unchanged sentences

for CDLTs established in 2018 will resume in 2024.

New CLFS rates will be established in 2025 based on data from 2019 to be reported

New CLFS rates will be established in 2028 based on data from 2026 to be reported in 2027 CLFS rates for Advanced Diagnostic

Laboratory Tests (ADLTs) will be updated annually.

New CLFS rates will be established in 2025 based on data from 2019 to be reported in

New CLFS rates will be established in 2028 based on data from 2026 to be reported in 2027 CLFS rates for Advanced Diagnostic Laboratory

Tests (ADLTs) will be updated annually.

CMS published its initial proposed CLFS rates

7 unchanged sentences

changes increase the cost of providing healthcare coverage to employees and their families.

Given the limited release of regulations

to guide compliance, as well as potential changes to the ACA, the exact impact to employers, including us, is uncertain.

Government payers,

such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical

testing services.

Given the limited release of regulations to

guide compliance, as well as potential changes to the ACA, the exact impact to employers, including us, is uncertain.

Government payers, such as Medicare and Medicaid,

have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services.

Although we currently do not provide any laboratory

2 unchanged sentences

payers to reduce utilization of and reimbursement for diagnostic information services.

One example of this is increased use of prior

authorization requirements.

We expect efforts to reduce reimbursements, to impose more stringent cost controls and to reduce utilization

of clinical test services will continue.

Pursuant to PAMA,

reimbursement rates for many clinical laboratory tests provided under Medicare were reduced from 2018 - 2020.

PAMA calls for further

revision of the Medicare CLFS for years after 2020, based on future surveys of market rates;

reimbursement rate reduction from 2024-26

is capped by PAMA at 15% annually.

PAMA’s next data collection and reporting period have been delayed, most recently by federal legislation

adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.

One example of this is increased use of prior authorization

requirements.

We expect efforts to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical

test services will continue.

Pursuant to PAMA, reimbursement rates for many

clinical laboratory tests provided under Medicare were reduced from 2018 - 2020.

PAMA calls for further revision of the Medicare CLFS

for years after 2020, based on future surveys of market rates;

reimbursement rate reduction from 2024-26 is capped by PAMA at 15% annually.

PAMA’s next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022,

which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.

In addition, CMS has adopted policies limiting

5 unchanged sentences

In addition, over the last several years, the

federal government has expanded its contracts with private health insurance plans for Medicare beneficiaries, called “Medicare

Advantage” programs, and has encouraged such beneficiaries to switch from the traditional programs to the private programs.

has been growth of health insurance plans offering Medicare Advantage programs, and of beneficiary enrollment in these programs.

have mandated that Medicaid beneficiaries enroll in private managed care arrangements.

In addition, state budget pressures have encouraged

states to consider several courses of action that may impact our business, such as delaying payments, reducing reimbursement, restricting

coverage eligibility, denying claims and service coverage restrictions.

Further, CMS has set goals for value-based reimbursement to be

achieved by 2030.

federal government has expanded its contracts with private health insurance plans for Medicare beneficiaries, called “Medicare Advantage”

programs, and has encouraged such beneficiaries to switch from the traditional programs to the private programs.

There has been growth

of health insurance plans offering Medicare Advantage programs, and of beneficiary enrollment in these programs.

States have mandated

that Medicaid beneficiaries enroll in private managed care arrangements.

In addition, state budget pressures have encouraged states to

consider several courses of action that may impact our business, such as delaying payments, reducing reimbursement, restricting coverage

eligibility, denying claims and service coverage restrictions.

Further, CMS has set goals for value-based reimbursement to be achieved

Reimbursement for Medicare services also is subject

to annual reduction under the Budget Control Act of 2011, and the Statutory Pay-As-You-Go Act of 2010.

From time to time, the

federal government has considered whether competitive bidding could be used to provide clinical testing services for Medicare beneficiaries

while maintaining quality and access to care.

From time to time, the federal government has

considered whether competitive bidding could be used to provide clinical testing services for Medicare beneficiaries while maintaining

quality and access to care.

Congress periodically considers cost-saving initiatives.

These initiatives have included

coinsurance for clinical testing services, co-payments for clinical testing and further laboratory physician fee schedule reductions.

Other steps taken

to reduce utilization and reimbursement include requirements to obtain diagnosis codes to obtain payment, increased documentation requirements,

limiting the allowable number of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment

Steps to reduce utilization

and reimbursement also discourage innovation and access to innovative solutions that we may offer.

Health plans and

other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services.

We face efforts by non-governmental

third-party payers, including health plans, to reduce utilization of and reimbursement for clinical testing services.

Examples include

increased use of prior authorization requirements and increased denial of coverage for services.

There is increased market activity regarding

alternative payment models, including bundled payment models.

We expect continuing efforts by third-party payers, including in their

rules, practices and policies, to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical

testing services.

ACOs and Independent Delivery Networks (IDNs), including hospitals and hospital health systems, also may undertake

efforts to reduce utilization of, or reimbursement for, diagnostic information services.

The healthcare industry

has experienced a trend of consolidation among health insurance plans, resulting in fewer but larger insurance plans with significant

bargaining power to negotiate fee arrangements with clinical testing providers.

The increased consolidation among health plans also has

increased pricing transparency, insurer bargaining power and the potential adverse impact of ceasing to be a contracted provider with

Health plans, and independent physician associations, may demand that clinical testing providers accept discounted fee structures

or assume all or a portion of the financial risk associated with providing testing services to their members through capitated payment

arrangements.

Some health plans also are reviewing test coding, evaluating coverage decisions and requiring preauthorization of certain

There are also an increasing number of patients enrolling in consumer driven products and high deductible plans that involve

greater patient cost-sharing.

Other steps taken to

reduce utilization and reimbursement include requirements to obtain diagnosis codes to obtain payment, increased documentation requirements,

limiting the allowable number of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment

Steps to reduce utilization

and reimbursement also discourage innovation and access to innovative solutions that we may offer.

The clinical testing

business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively

it could have a material adverse effect on our revenues and profitability.

The laboratory testing

industry is fragmented and highly competitive.

These initiatives have included coinsurance for clinical

testing services, co-payments for clinical testing and further laboratory physician fee schedule reductions.

Other steps taken to reduce utilization and reimbursement

include requirements to obtain diagnosis codes to obtain payment, increased documentation requirements, limiting the allowable number

of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment denials.

Steps to reduce utilization and reimbursement

also discourage innovation and access to innovative solutions that we may offer.

Health plans and other third parties have taken

steps to reduce the utilization and reimbursement of health services, including clinical testing services.

We face efforts by non-governmental third-party

payers, including health plans, to reduce utilization of and reimbursement for clinical testing services.

Examples include increased use

of prior authorization requirements and increased denial of coverage for services.

There is increased market activity regarding alternative

payment models, including bundled payment models.

We expect continuing efforts by third-party payers, including in their rules, practices

and policies, to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical testing services.

ACOs and Independent Delivery Networks (IDNs), including hospitals and hospital health systems, also may undertake efforts to reduce utilization

of, or reimbursement for, diagnostic information services.

The healthcare industry has experienced a trend

of consolidation among health insurance plans, resulting in fewer but larger insurance plans with significant bargaining power to negotiate

fee arrangements with clinical testing providers.

The increased consolidation among health plans also has increased pricing transparency,

insurer bargaining power and the potential adverse impact of ceasing to be a contracted provider with an insurer.

Health plans, and independent

physician associations, may demand that clinical testing providers accept discounted fee structures or assume all or a portion of the

financial risk associated with providing testing services to their members through capitated payment arrangements.

Some health plans also

are reviewing test coding, evaluating coverage decisions and requiring preauthorization of certain testing.

There are also an increasing

number of patients enrolling in consumer driven products and high deductible plans that involve greater patient cost-sharing.

Other steps taken to reduce utilization and reimbursement

include requirements to obtain diagnosis codes to obtain payment, increased documentation requirements, limiting the allowable number

of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment denials.

Steps to reduce utilization and reimbursement

also discourage innovation and access to innovative solutions that we may offer.

The Laboratory Services MSO Acquisition will

result in organizational changes that could create significant growth for our business.

If we fail to effectively manage this growth and

adapt our business structure in a manner that preserves our reputation, then our business, financial condition and results of operations

could be harmed.

On February 9, 2023, we acquired 40% of all the

issued and outstanding equity interests of Lab Services MSO.

The Laboratory Services MSO Acquisition has resulted in significant growth

in our operations.

We have incurred and will continue to incur significant expenditures and the allocation of management time to assimilate

Lab Services MSO in a manner that preserves the key aspects of our business, but there can be no assurance that we will be successful

in our efforts.

If we do not effectively integrate Lab Services MSO, the effectiveness of our business growth could suffer, and our reputation

could be harmed, each of which could adversely impact our business, financial condition and results of operations.

The success of our business will depend, in part,

on our ability to realize our anticipated benefits and opportunities from the acquisition.

We can provide no assurance that the anticipated

benefits of the Laboratory Services MSO Acquisition will be fully realized in the time frame anticipated or at all.

The failure to meet

the challenges involved in integrating the two businesses could cause an interruption of business activities, an increase in operating

costs or lower anticipated financial performance.

Our failure to achieve the anticipated and the potential benefits underlying our reasons

for the Laboratory Services MSO Acquisition could have a material adverse impact on our business, financial condition and results of operations.

The clinical testing business is highly competitive,

and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse

effect on our revenues and profitability.

The laboratory testing industry is fragmented

and highly competitive.

We primarily compete with three types of clinical testing providers:

commercial clinical

laboratories IDN-affiliated laboratories and physician-office laboratories.

Our largest commercial clinical laboratory competitors are

Quest Diagnostic Laboratories and Laboratory Corporation of America.

In addition, we compete with many smaller regional and local commercial

clinical laboratories, specialized advanced laboratories and providers of consumer-initiated testing.

There also has been a trend among

physician practices to establish their own histology laboratory capabilities and/or bring pathologists into their practices, thereby

reducing referrals from these practices and increasing the competitive position of these practices.

The commercial laboratory

business is intensely competitive both in terms of price and service.

Pricing of laboratory testing services is often one of the most

significant factors used by physicians, third-party payers and consumers in selecting a laboratory.

As a result of significant consolidation

in the commercial laboratory industry, larger commercial laboratory providers are able to increase cost efficiencies afforded by large-scale

automated testing.

commercial clinical laboratories IDN-affiliated

laboratories and physician-office laboratories.

Our largest commercial clinical laboratory competitors are Quest Diagnostic Laboratories

and Laboratory Corporation of America.

In addition, we compete with many smaller regional and local commercial clinical laboratories,

specialized advanced laboratories and providers of consumer-initiated testing.

There also has been a trend among physician practices to

establish their own histology laboratory capabilities and/or bring pathologists into their practices, thereby reducing referrals from

these practices and increasing the competitive position of these practices.

The commercial laboratory business is intensely

competitive both in terms of price and service.

Pricing of laboratory testing services is often one of the most significant factors used

by physicians, third-party payers and consumers in selecting a laboratory.

As a result of significant consolidation in the commercial

laboratory industry, larger commercial laboratory providers are able to increase cost efficiencies afforded by large-scale automated testing.

This consolidation results in greater price competition.

Our laboratory services business may be unable to increase

cost efficiencies sufficiently, if at all, and as a result, its net earnings and cash flows could be negatively impacted by such price

We may face increased competition from health system laboratories, due to physicians within those systems directing their

testing to the health system laboratory and away from us, and as those laboratories seek to expand their testing volume from unaffiliated

physicians in their service areas.

We may also face competition from companies that do not comply with existing laws or regulations or

otherwise disregard compliance standards in the industry.

Additionally, we may also face changes in fee schedules, competitive bidding

for laboratory services, or other actions or pressures reducing payment schedules as a result of increased or additional competition.

These competitive pressures may affect the attractiveness or profitability of our laboratory services business, and could adversely affect

our financial results.

The diagnostic information

services industry also is faced with changing technology and new product introductions.

Competitors may compete using advanced technology,

including technology that enables more convenient or cost-effective testing.

Digital pathology, still in an emerging state, is an example

Competitors also may compete on the basis of new service offerings.

Competitors also may offer testing to be performed outside

of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices;

testing that can be performed by IDNs in their own laboratories;

and (3) home testing that can be carried out without requiring the services

of outside providers.

Failure to obtain

and retain new customers, the loss of existing customers or material contracts, or a reduction in services or tests ordered or specimens

submitted by existing customers, or the inability to retain existing and/or create new relationships with health systems could impact

our ability to successfully grow our business.

maintain and grow its business, we need to obtain and retain new customers and business partners.

In addition, a reduction in tests ordered

or specimens submitted by existing customers, a decrease in demand for our services from existing customers, or the loss of existing

contracts, without offsetting growth in its customer base, could impact our ability to successfully grow its business and could have

a material adverse effect on our revenues and profitability.

We compete primarily on the basis of the quality of services, reporting

and information systems, reputation in the medical community, the pricing of services and ability to employ qualified personnel.

Our failure to successfully compete on any of these factors could result in the loss of existing customers, an inability to gain new

customers and a reduction in our business.

Discontinuation or

recalls of existing testing products;

Our laboratory services business may be unable to increase cost efficiencies

sufficiently, if at all, and as a result, its net earnings and cash flows could be negatively impacted by such price competition.

face increased competition from health system laboratories, due to physicians within those systems directing their testing to the health

system laboratory and away from us, and as those laboratories seek to expand their testing volume from unaffiliated physicians in their

service areas.

We may also face competition from companies that do not comply with existing laws or regulations or otherwise disregard

compliance standards in the industry.

Additionally, we may also face changes in fee schedules, competitive bidding for laboratory services,

or other actions or pressures reducing payment schedules as a result of increased or additional competition.

These competitive pressures

may affect the attractiveness or profitability of our laboratory services business, and could adversely affect our financial results.

The diagnostic information services industry also

is faced with changing technology and new product introductions.

Competitors may compete using advanced technology, including technology

that enables more convenient or cost-effective testing.

Digital pathology, still in an emerging state, is an example of this.

also may compete on the basis of new service offerings.

Competitors also may offer testing to be performed outside of a commercial clinical

laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices;

(2) advanced testing that can be performed

by IDNs in their own laboratories;

and (3) home testing that can be carried out without requiring the services of outside providers.

Failure to obtain and retain new customers,

the loss of existing customers or material contracts, or a reduction in services or tests ordered or specimens submitted by existing customers,

or the inability to retain existing and/or create new relationships with health systems could impact our ability to successfully grow

our business.

To maintain and grow its business, we need to

obtain and retain new customers and business partners.

In addition, a reduction in tests ordered or specimens submitted by existing customers,

a decrease in demand for our services from existing customers, or the loss of existing contracts, without offsetting growth in its customer

base, could impact our ability to successfully grow its business and could have a material adverse effect on our revenues and profitability.

We compete primarily on the basis of the quality of services, reporting and information systems, reputation in the medical community,

the pricing of services and ability to employ qualified personnel.

Our failure to successfully compete on any of these factors could result

in the loss of existing customers, an inability to gain new customers and a reduction in our business.

Discontinuation or recalls of existing testing

failure to develop or acquire licenses for new or improved testing technologies;

or our customers

using new technologies to perform their own tests could adversely affect our business.

time to time, manufacturers discontinue or recall reagents, test kits or instruments used by us to perform laboratory testing.

Such discontinuations

or recalls could adversely affect our costs, testing volume and revenue.

commercial laboratory industry is subject to changing technology and new product introductions.

If we are unable to license new or improved

technologies to expand its esoteric testing operations, its testing methods may become outdated when compared with our competition, and

testing volume and revenue may be materially and adversely affected.

addition, advances in technology may lead to the development of more cost-effective technologies such as point-of-care testing equipment

that can be operated by physicians or other healthcare providers (including physician assistants, nurse practitioners and certified nurse

midwives, generally referred to herein as physicians) in their offices or by patients themselves without requiring the services of freestanding

clinical laboratories.

Development of such technology and its use by our customers could reduce the demand for its laboratory testing

services and the utilization of certain tests offered by us and negatively impact its revenues.

most commercial laboratory testing is categorized as high or moderate complexity, and thereby is subject to extensive and costly regulation

under Clinical Laboratory Improvement Act (CLIA).

The cost of compliance with CLIA makes it impractical for most physicians to operate

clinical laboratories in their offices, and other laws limit the ability of physicians to have ownership in a laboratory and to refer

tests to such a laboratory.

Manufacturers of laboratory equipment and test kits could seek to increase their sales by marketing point-of-care

laboratory equipment to physicians and by selling test kits approved for home or physician office use to both physicians and patients.

Diagnostic tests approved for home use are automatically deemed to be “waived” tests under CLIA and may be performed in physician

office laboratories as well as by patients in their homes with minimal regulatory oversight.

Other tests meeting certain FDA criteria

also may be classified as “waived” for CLIA purposes.

The FDA has regulatory responsibility over instruments, test kits,

reagents and other devices used by clinical laboratories, and it has taken responsibility from the U.S.

Centers for Disease Control and

Prevention for classifying the complexity of tests for CLIA purposes.

Increased approval of “waived” test kits could lead

to increased testing by physicians in their offices or by patients at home, which could affect our market for laboratory testing services

and negatively impact its revenues.

Changes or disruption

in services supplies, or transportation provided by third parties have impacted and could continue to impact or adversely affect our

depend on third parties to provide supplies and services critical to our laboratory testing business.

We are heavily reliant on third-party

ground and air travel for transport of clinical trial and diagnostic testing supplies and specimens, research products, and people.

significant disruption to these travel systems, or our access to them, could have a material adverse effect on our business.

reliant on an extensive network of third-party suppliers and vendors of certain services and products, including for certain animal populations.

Disruptions to the continued supply, or increases in costs, of these services, products, or animal populations may arise from export/import

restrictions or embargoes, political or economic instability, pressure from animal rights activists, adverse weather, natural disasters,

public health crises, transportation disruptions, cyber-attacks, or other causes, as well as from termination of relationships with suppliers

or vendors for their failure to follow our performance standards and requirements.

Disruption of supply and services has impacted and

could continue to impact or have a material adverse effect on our business.

Continued and increased

consolidation of pharmaceutical, biotechnology and medical device companies, health systems, physicians and other customers could adversely

affect our business.

healthcare companies and providers, including pharmaceutical, biotechnology and medical device companies, health systems and physician

practices are consolidating through mergers, acquisitions, joint ventures and other types of transactions and collaborations.

to these more traditional horizontal mergers that involve entities that previously competed against each other, the healthcare industry

is experiencing an increase in vertical mergers, which involve entities that previously did not offer competing goods or services.

the healthcare industry consolidates, competition to provide goods and services may become more intense, and vertical mergers may give

those combined companies greater control over more aspects of healthcare, including increased bargaining power.

This competition and

increased customer bargaining power may adversely affect the price and volume of our services.

addition, as the broader healthcare industry trend of consolidation continues, including the acquisition of physician practices by health

systems, relationships with hospital-based health systems and integrated delivery networks are becoming more important.

Our laboratory

services business’ inability to retain its existing relationships with physicians if they become part of healthcare systems and

networks and/or to create new relationships could impact its ability to successfully grow.

Changes, including

changes in interpretation, in payer regulations, policies or approvals, or changes in laws, regulations or policies in the U.S.

may adversely affect us.

and state government payers, such as Medicare and Medicaid, as well as insurers, including MCOs, have increased their efforts to control

the cost, utilization and delivery of healthcare services.

From time to time, Congress has considered and implemented changes in Medicare

fee schedules in conjunction with budgetary legislation.

The first phase of reductions pursuant to PAMA came into effect on January 1,

2018, and will continue annually subject to certain delays in implementation and phase-in limits through 2026, and without limitations

for subsequent periods.

Further reductions due to changes in policy regarding coverage of tests or other requirements for payment, such

as prior authorization, diagnosis code and other claims edits, may be implemented from time to time.

Reimbursement for pathology services

performed by us is also subject to statutory and regulatory reduction.

Reductions in the reimbursement rates and changes in payment policies

of other third-party payers may occur as well.

Such changes in the past have resulted in reduced payments as well as added costs and

have decreased test utilization for the commercial laboratory industry by adding more complex new regulatory and administrative requirements.

Further changes in third-party payer regulations, policies, or laboratory benefit or utilization management programs may have a material

adverse effect on our business.

Actions by federal and state agencies regulating insurance, including healthcare exchanges, or changes

in other laws, regulations, or policies may also have a material adverse effect upon our business.

Our business could

be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations

of, the law or regulations of CLIA, Medicare, Medicaid or other national, state or local agencies in the U.S.

and other countries where

we operate laboratories currently and in the future.

commercial laboratory testing industry is subject to extensive U.S.

regulation, and many of these statutes and regulations have not been

interpreted by the courts.

CLIA extends federal oversight to virtually all clinical laboratories operating in the U.S.

by requiring that

they be certified by the federal government or by a federally approved accreditation agency.

The sanction for failure to comply with

CLIA requirements may be suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct

business, as well as significant fines and/or criminal penalties.

or our customers using new technologies to

perform their own tests could adversely affect our business.

From time to time, manufacturers discontinue or

recall reagents, test kits or instruments used by us to perform laboratory testing.

Such discontinuations or recalls could adversely affect

our costs, testing volume and revenue.

The commercial laboratory industry is subject

to changing technology and new product introductions.

If we are unable to license new or improved technologies to expand its esoteric

testing operations, its testing methods may become outdated when compared with our competition, and testing volume and revenue may be

materially and adversely affected.

In addition, advances in technology may lead to

the development of more cost-effective technologies such as point-of-care testing equipment that can be operated by physicians or other

healthcare providers (including physician assistants, nurse practitioners and certified nurse midwives, generally referred to herein as

physicians) in their offices or by patients themselves without requiring the services of freestanding clinical laboratories.

of such technology and its use by our customers could reduce the demand for its laboratory testing services and the utilization of certain

tests offered by us and negatively impact its revenues.

Currently, most commercial laboratory testing

is categorized as high or moderate complexity, and thereby is subject to extensive and costly regulation under the Clinical Laboratory

Improvement Act (CLIA).

The cost of compliance with CLIA makes it impractical for most physicians to operate clinical laboratories in

their offices, and other laws limit the ability of physicians to have ownership in a laboratory and to refer tests to such a laboratory.

Manufacturers of laboratory equipment and test kits could seek to increase their sales by marketing point-of-care laboratory equipment

to physicians and by selling test kits approved for home or physician office use to both physicians and patients.

Diagnostic tests approved

for home use are automatically deemed to be “waived” tests under CLIA and may be performed in physician office laboratories

as well as by patients in their homes with minimal regulatory oversight.

Other tests meeting certain FDA criteria also may be classified

as “waived” for CLIA purposes.

The FDA has regulatory responsibility over instruments, test kits, reagents and other devices

used by clinical laboratories, and it has taken responsibility from the U.S.

Centers for Disease Control and Prevention for classifying

the complexity of tests for CLIA purposes.

Increased approval of “waived” test kits could lead to increased testing by physicians

in their offices or by patients at home, which could affect our market for laboratory testing services and negatively impact its revenues.

Changes or disruption in services supplies,

or transportation provided by third parties have impacted and could continue to impact or adversely affect our business.

We depend on third parties to provide supplies

and services critical to our laboratory services business.

We are heavily reliant on third-party ground and air travel for transport of

clinical trial and diagnostic testing supplies and specimens, research products, and people.

A significant disruption to these travel

systems, or our access to them, could have a material adverse effect on our business.

We are also reliant on an extensive network of third-party

suppliers and vendors of certain services and products, including for certain animal populations.

Disruptions to the continued supply,

or increases in costs, of these services, products, or animal populations may arise from export/import restrictions or embargoes, political

or economic instability, pressure from animal rights activists, adverse weather, natural disasters, public health crises, transportation

disruptions, cyber-attacks, or other causes, as well as from termination of relationships with suppliers or vendors for their failure

to follow our performance standards and requirements.

Disruption of supply and services has impacted and could continue to impact or have

a material adverse effect on our business.

Continued and increased consolidation of pharmaceutical,

biotechnology and medical device companies, health systems, physicians and other customers could adversely affect our business.

Many healthcare companies and providers, including

pharmaceutical, biotechnology and medical device companies, health systems and physician practices are consolidating through mergers,

acquisitions, joint ventures and other types of transactions and collaborations.

In addition to these more traditional horizontal mergers

that involve entities that previously competed against each other, the healthcare industry is experiencing an increase in vertical mergers,

which involve entities that previously did not offer competing goods or services.

As the healthcare industry consolidates, competition

to provide goods and services may become more intense, and vertical mergers may give those combined companies greater control over more

aspects of healthcare, including increased bargaining power.

This competition and increased customer bargaining power may adversely affect

the price and volume of our services.

In addition, as the broader healthcare industry

trend of consolidation continues, including the acquisition of physician practices by health systems, relationships with hospital-based

health systems and integrated delivery networks are becoming more important.

Our laboratory services business’ inability to retain

its existing relationships with physicians if they become part of healthcare systems and networks and/or to create new relationships could

impact its ability to successfully grow.

Changes, including changes in interpretation,

in payer regulations, policies or approvals, or changes in laws, regulations or policies in the U.S.

or globally, may adversely affect

and state government payers, such as Medicare

and Medicaid, as well as insurers, including MCOs, have increased their efforts to control the cost, utilization and delivery of healthcare

From time to time, Congress has considered and implemented changes in Medicare fee schedules in conjunction with budgetary legislation.

The first phase of reductions pursuant to PAMA came into effect on January 1, 2018, and will continue annually subject to certain delays

in implementation and phase-in limits through 2026, and without limitations for subsequent periods.

Further reductions due to changes

in policy regarding coverage of tests or other requirements for payment, such as prior authorization, diagnosis code and other claims

edits, may be implemented from time to time.

Reimbursement for pathology services performed by us is also subject to statutory and regulatory

Reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur as well.

in the past have resulted in reduced payments as well as added costs and have decreased test utilization for the commercial laboratory

industry by adding more complex new regulatory and administrative requirements.

Further changes in third-party payer regulations, policies,

or laboratory benefit or utilization management programs may have a material adverse effect on our business.

Actions by federal and state

agencies regulating insurance, including healthcare exchanges, or changes in other laws, regulations, or policies may also have a material

adverse effect upon our business.

Our business could be harmed from the loss

or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of, the law or regulations

of CLIA, Medicare, Medicaid or other national, state or local agencies in the U.S.

and other countries where we operate laboratories currently

and in the future.

The commercial laboratory testing industry is

subject to extensive U.S.

regulation, and many of these statutes and regulations have not been interpreted by the courts.

federal oversight to virtually all clinical laboratories operating in the U.S.

by requiring that they be certified by the federal government

or by a federally approved accreditation agency.

The sanction for failure to comply with CLIA requirements may be suspension, revocation

or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal

In addition, we are subject to regulation under state law.

may require that laboratories and/or laboratory personnel meet certain qualifications, specify certain quality controls or require maintenance

of certain records.

In the future, we may also operate laboratories outside of the U.S.

and become subject to laws governing its laboratory

operations in the other countries where it operates.

statutes and regulations could be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would

adversely affect our business.

Potential sanctions for violation of these statutes and regulations include significant fines and the

suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our business.

In addition, compliance with future legislation could impose additional requirements on us, which may be costly.

Failure of us or

our third-party service providers to comply with privacy and security laws and regulations could result in fines, penalties and damage

to our reputation with customers and have a material adverse effect upon our business.

we and our third-party service providers do not comply with existing or new laws and regulations related to protecting the privacy and

security of personal or health information, we could be subject to monetary fines, civil penalties or criminal sanctions.

the U.S., HIPAA privacy and security regulations, including the expanded requirements under HITECH, establish comprehensive standards

with respect to the use and disclosure of protected health information (PHI), by covered entities, in addition to setting standards to

protect the confidentiality, integrity and security of PHI.

restricts our ability to use or disclose PHI, without patient authorization, for purposes other than payment, treatment or healthcare

operations (as defined by HIPAA), except for disclosures for various public policy purposes and other permitted purposes outlined in

the privacy regulations.

HIPAA and HITECH provide for significant fines and other penalties for wrongful use or disclosure of PHI in

violation of the privacy and security regulations, including potential civil and criminal fines and penalties.

The regulations establish

a complex regulatory framework on a variety of subjects, including:

circumstances under which the use and disclosure of PHI are permitted or required without

a specific authorization by the patient, including, but not limited to, treatment purposes,

activities to obtain payments for our services, and its healthcare operations activities;

patient’s rights to access, amend and receive an accounting of certain disclosures

content of notices of privacy practices for PHI;

● administrative,

technical and physical safeguards required of entities that use or receive PHI;

protection of computing systems maintaining electronic PHI.

have implemented policies and procedures designed to comply with the HIPAA privacy and security requirements as applicable.

and security regulations establish a “floor” and do not supersede state laws that are more stringent.

Therefore, we are required

to comply with both additional federal privacy and security regulations and varying state privacy and security laws.

In addition, federal

and state laws that protect the privacy and security of patient information may be subject to enforcement and interpretations by various

governmental authorities and courts, resulting in complex compliance issues.

For example, we could incur damages under state laws, including

pursuant to an action brought by a private party for the wrongful use or disclosure of health information or other personal information.

Failure to comply

with U.S., state or local environmental, health and safety laws and regulations could result in fines, penalties and loss of licensure,

and have a material adverse effect upon us.

are subject to licensing and regulation under laws and regulations relating to the protection of the environment and human health and

safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous

waste and radioactive materials, as well as regulations relating to the safety and health of laboratory employees.

Failure to comply

with these laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement

actions that would have a material adverse effect on its business.

In addition, compliance with future legislation could impose additional

requirements on us that may be costly.

system is evolving and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we

fail to adapt.

system continues to evolve.

State laws may require that laboratories and/or laboratory personnel

meet certain qualifications, specify certain quality controls or require maintenance of certain records.

In the future, we may also operate

laboratories outside of the U.S.

and become subject to laws governing its laboratory operations in the other countries where it operates.

Applicable statutes and regulations could be interpreted

or applied by a prosecutorial, regulatory or judicial authority in a manner that would adversely affect our business.

Potential sanctions

for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates

and authorizations, which could have a material adverse effect on our business.

In addition, compliance with future legislation could

impose additional requirements on us, which may be costly.

Failure of us or our third-party service providers

to comply with privacy and security laws and regulations could result in fines, penalties and damage to our reputation with customers

and have a material adverse effect upon our business.

If we and our third-party service providers do

not comply with existing or new laws and regulations related to protecting the privacy and security of personal or health information,

we could be subject to monetary fines, civil penalties or criminal sanctions.

In the U.S., HIPAA privacy and security regulations,

including the expanded requirements under HITECH, establish comprehensive standards with respect to the use and disclosure of protected

health information (PHI), by covered entities, in addition to setting standards to protect the confidentiality, integrity and security

HIPAA restricts our ability to use or disclose

PHI, without patient authorization, for purposes other than payment, treatment or healthcare operations (as defined by HIPAA), except

for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations.

HIPAA and HITECH

provide for significant fines and other penalties for wrongful use or disclosure of PHI in violation of the privacy and security regulations,

including potential civil and criminal fines and penalties.

The regulations establish a complex regulatory framework on a variety of subjects,

● the circumstances under which

the use and disclosure of PHI are permitted or required without a specific authorization by the patient, including, but not limited to,

treatment purposes, activities to obtain payments for our services, and its healthcare operations activities;

● a patient’s rights to

access, amend and receive an accounting of certain disclosures of PHI;

● the content of notices of privacy

practices for PHI;

● administrative, technical and

physical safeguards required of entities that use or receive PHI;

● the protection of computing

systems maintaining electronic PHI.

We have implemented policies and procedures designed

to comply with the HIPAA privacy and security requirements as applicable.

The privacy and security regulations establish a “floor”

and do not supersede state laws that are more stringent.

Therefore, we are required to comply with both additional federal privacy and

security regulations and varying state privacy and security laws.

In addition, federal and state laws that protect the privacy and security

of patient information may be subject to enforcement and interpretations by various governmental authorities and courts, resulting in

complex compliance issues.

For example, we could incur damages under state laws, including pursuant to an action brought by a private

party for the wrongful use or disclosure of health information or other personal information.

Failure to comply with U.S., state or local

environmental, health and safety laws and regulations could result in fines, penalties and loss of licensure, and have a material adverse

effect upon us.

We are subject to licensing and regulation under

laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating

to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as

regulations relating to the safety and health of laboratory employees.

Failure to comply with these laws and regulations could subject

us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions that would have a material adverse

effect on its business.

In addition, compliance with future legislation could impose additional requirements on us that may be costly.

healthcare system is evolving and

medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt.

healthcare system continues to evolve.

Significant change is taking place in the healthcare system.

For example, value-based reimbursement is increasing;

CMS has set goals for value-based reimbursement to be achieved by 2030.

Patients are encouraged to take increased interest in and responsibility

for, and often are bearing increased responsibility for payment for, their healthcare.

Healthcare industry participants are evolving

and consolidating.

Healthcare services increasingly are being provided by non-traditional providers ( e.g ., physician assistants),

in non-traditional venues ( e.g ., retail medical clinics, urgent care centers) and using new technologies ( e.g ., telemedicine,

digital pathology).

Utilization of the healthcare system is being influenced by several factors and may result in a decline in the demand

for diagnostic information services.

In addition, we believe

that clinical testing market fundamentals are changing.

We believe that PAMA-driven reimbursement pressure remains a catalyst for structural

change in the market.

We also believe that health plans and consumers increasingly are focusing on driving better value in laboratory

testing services.

We expect that the evolution of the healthcare industry will continue, and that industry change is likely to be extensive.

Failure to establish,

and perform to, appropriate quality standards, or to assure that the appropriate standard of quality is observed in the performance of

our diagnostic information services, could adversely affect the results of our operations and adversely impact our reputation.

The provision of diagnostic

information services involves certain inherent risks.

The services that we provide are intended to provide information in providing patient

Therefore, users of our services may have a greater sensitivity to errors than the users of services or products that are intended

for other purposes.

Negligence in performing

our services can lead to injury or other adverse events.

We may be sued under physician liability or other liability law for acts or

omissions by our pathologists, laboratory personnel and IDN employees who are under our supervision.

We are subject to the attendant

risk of substantial damages awards in excess of our insurance coverage and risk to our reputation.

We are subject to

numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business

activities may be impacted, if we fail to comply.

Our business is subject

to or impacted by extensive and frequently changing laws and regulations in the United States (including at both the federal and state

levels) and the other jurisdictions in which we engage in business.

While we seek to conduct our business in compliance with all applicable

laws, many of the laws and regulations applicable to us are vague or indefinite and have not been extensively interpreted by the courts,

including many of those relating to:

and reimbursement of clinical testing;

● certification

or licensure of clinical laboratories;

anti-self-referral and anti-kickback laws and regulations;

laws and regulations administered by the FDA;

corporate practice of medicine;

● operational,

personnel and quality requirements intended to ensure that clinical testing services are

accurate, reliable and timely;

fee splitting;

● relationships

with physicians and IDNs;

to consumers;

of patient data and other personal information;

and health of laboratory employees;

transportation and disposal of medical specimens, infectious and hazardous waste and radioactive

These laws and regulations

may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes

in our operations, including our pricing and/or billing practices.

We may not be able to maintain, renew or secure required permits,

licenses or any other regulatory approvals needed to operate our business or commercialize our services.

If we fail to comply with applicable

laws and regulations, or if we fail to maintain, renew or obtain necessary permits, licenses and approvals, we could suffer civil and

criminal penalties, fines, exclusion from participation in governmental healthcare programs and the loss of various licenses, certificates

and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims.

If any of the

foregoing were to occur, our reputation could be damaged and important business relationships with third parties could be adversely affected.

We also are subject

from time to time to qui tam claims brought by former employees or other “whistleblowers.” The federal and state governments

continue aggressive enforcement efforts against perceived healthcare fraud.

Legislative provisions relating to healthcare fraud and abuse

provide government enforcement personnel substantial funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse.

In addition, the government has substantial leverage in negotiating settlements since the amount of potential damages far exceeds the

rates at which we are reimbursed for our services, and the government has the remedy of excluding a non-compliant provider from participation

in the Medicare and Medicaid programs.

Regardless of merit or eventual outcome, these types of investigations and related litigation

can result in:

of management time and attention;

● expenditure

of large amounts of cash on legal fees, costs and payment of damages;

to our administrative, billing or other operating costs;

● limitations

on our ability to continue some of our operations;

● enforcement

actions, fines and penalties or the assertion of private litigation claims and damages;

to the amount of reimbursement related to diagnostic information services performed;

affects to important business relationships with third parties;

demand for our services;

to our reputation.

Changes in applicable

laws and regulations may result in existing practices becoming more restricted, or subject our existing or proposed services to additional

costs, delay, modification or withdrawal.

CMS has set goals for

value-based reimbursement to be achieved by 2030.

Patients are encouraged to take increased interest in and responsibility for, and often

are bearing increased responsibility for payment for, their healthcare.

Healthcare industry participants are evolving and consolidating.

Healthcare services increasingly are being provided by non-traditional providers ( e.g ., physician assistants), in non-traditional

venues ( e.g ., retail medical clinics, urgent care centers) and using new technologies ( e.g ., telemedicine, digital pathology).

Utilization of the healthcare system is being influenced by several factors and may result in a decline in the demand for diagnostic information

In addition, we believe that clinical testing

market fundamentals are changing.

We believe that PAMA-driven reimbursement pressure remains a catalyst for structural change in the market.

We also believe that health plans and consumers increasingly are focusing on driving better value in laboratory testing services.

that the evolution of the healthcare industry will continue, and that industry change is likely to be extensive.

Failure to establish and perform to appropriate

quality standards, or to assure that the appropriate standard of quality is observed in the performance of our diagnostic information

services, could adversely affect the results of our operations and adversely impact our reputation.

The provision of diagnostic information services

involves certain inherent risks.

The services that we provide are intended to provide information in providing patient care.

users of our services may have a greater sensitivity to errors than the users of services or products that are intended for other purposes.

Negligence in performing our services can lead

to injury or other adverse events.

We may be sued under physician liability or other liability law for acts or omissions by our pathologists,

laboratory personnel and IDN employees who are under our supervision.

We are subject to the attendant risk of substantial damages awards

in excess of our insurance coverage and risk to our reputation.

We are subject to numerous legal and regulatory

requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if

we fail to comply.

Our business is subject to or impacted by extensive

and frequently changing laws and regulations in the United States (including at both the federal and state levels) and the other jurisdictions

in which we engage in business.

While we seek to conduct our business in compliance with all applicable laws, many of the laws and regulations

applicable to us are vague or indefinite and have not been extensively interpreted by the courts, including many of those relating to:

● billing and reimbursement of

clinical testing;

● certification or licensure

of clinical laboratories;

● the anti-self-referral and

anti-kickback laws and regulations;

● the laws and regulations administered

● the corporate practice of medicine;

● operational, personnel and

quality requirements intended to ensure that clinical testing services are accurate, reliable and timely;

● physician fee splitting;

● relationships with physicians

● marketing to consumers;

● privacy of patient data and

other personal information;

● safety and health of laboratory

● handling, transportation and

disposal of medical specimens, infectious and hazardous waste and radioactive materials.

These laws and regulations may be interpreted

or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations, including

our pricing and/or billing practices.

We may not be able to maintain, renew or secure required permits, licenses or any other regulatory

approvals needed to operate our business or commercialize our services.

If we fail to comply with applicable laws and regulations, or

if we fail to maintain, renew or obtain necessary permits, licenses and approvals, we could suffer civil and criminal penalties, fines,

exclusion from participation in governmental healthcare programs and the loss of various licenses, certificates and authorizations necessary

to operate our business, as well as incur additional liabilities from third-party claims.

If any of the foregoing were to occur, our reputation

could be damaged and important business relationships with third parties could be adversely affected.

We also are subject from time to time to qui tam

claims brought by former employees or other “whistleblowers.” The federal and state governments continue aggressive enforcement

efforts against perceived healthcare fraud.

Legislative provisions relating to healthcare fraud and abuse provide government enforcement

personnel substantial funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse.

In addition, the government

has substantial leverage in negotiating settlements since the amount of potential damages far exceeds the rates at which we are reimbursed

for our services, and the government has the remedy of excluding a non-compliant provider from participation in the Medicare and Medicaid

Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:

● diversion of management time

and attention;

● expenditure of large amounts

of cash on legal fees, costs and payment of damages;

● increases to our administrative,

billing or other operating costs;

● limitations on our ability

to continue some of our operations;

● enforcement actions, fines

and penalties or the assertion of private litigation claims and damages;

● decreases to the amount of

reimbursement related to diagnostic information services performed;

● adverse affects to important

business relationships with third parties;

● decreased demand for our services;

● injury to our reputation.

Changes in applicable laws and regulations may

result in existing practices becoming more restricted, or subject our existing or proposed services to additional costs, delay, modification

or withdrawal.

Such changes also could require us to modify our business objectives.

Failure to accurately

bill for our services, or to comply with applicable laws relating to government healthcare programs, could have a material adverse effect

on our business .

Billing for diagnostic

information services is complex and subject to extensive and non-uniform rules and administrative requirements.

Depending on the billing

arrangement and applicable law, we bill various payers, such as patients, insurance companies, Medicare, Medicaid, clinicians, IDNs and

employer groups.

The majority of billing and related operations for our Company are being provided by a third party under our oversight.

Failure to accurately bill for our services could have a material adverse effect on our business.

In addition, failure to comply with

applicable laws relating to billing government healthcare programs may result in various consequences, including:

civil and criminal

fines and penalties, exclusion from participation in governmental healthcare programs and the loss of various licenses, certificates

and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims.

Certain violations

of these laws may also provide the basis for a civil remedy under the federal False Claims Act, including fines and damages of up to

three times the amount claimed.

The qui tam provisions of the federal False Claims Act and similar provisions in certain state false

claims acts allow private individuals to bring lawsuits against healthcare companies on behalf of government payers, private payers and/or

patients alleging inappropriate billing practices.

Although we believe

that we are in compliance, in all material respects, with applicable laws and regulations, there can be no assurance that a regulatory

agency or tribunal would not reach a different conclusion.

The federal or state government may bring claims based on our current practices,

which we believe are lawful.

The federal and state governments have substantial leverage in negotiating settlements since the amount

of potential damages and fines far exceeds the rates at which we are reimbursed, and the government has the remedy of excluding a non-compliant

provider from participation in the Medicare and Medicaid programs.

We believe that federal and state governments continue aggressive

enforcement efforts against perceived healthcare fraud.

Legislative provisions relating to healthcare fraud and abuse provide government

enforcement personnel with substantial funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse.

Inflationary pressures

could adversely impact us because of increases in the costs of materials, supplies and services, and increased labor and people-related

Inflationary pressures

have resulted in increases in the costs of the testing equipment, supplies and other goods and services that we purchase from manufacturers,

suppliers and others.

Inflationary pressures, along with the competition for labor, have also resulted in a rise of our labor costs,

which include the costs of compensation, benefits, and recruiting and training new hires.

Our ability to raise the prices and fees we

charge for the services we provide is limited.

Failure to accurately bill for our services,

or to comply with applicable laws relating to government healthcare programs, could have a material adverse effect on our business .

Billing for diagnostic information services is

complex and subject to extensive and non-uniform rules and administrative requirements.

Depending on the billing arrangement and applicable

law, we bill various payers, such as patients, insurance companies, Medicare, Medicaid, clinicians, IDNs and employer groups.

of billing and related operations for our Company are being provided by a third party under our oversight.

Failure to accurately bill

for our services could have a material adverse effect on our business.

In addition, failure to comply with applicable laws relating to

billing government healthcare programs may result in various consequences, including:

civil and criminal fines and penalties, exclusion

from participation in governmental healthcare programs and the loss of various licenses, certificates and authorizations necessary to

operate our business, as well as incur additional liabilities from third-party claims.

Certain violations of these laws may also provide

the basis for a civil remedy under the federal False Claims Act, including fines and damages of up to three times the amount claimed.

The qui tam provisions of the federal False Claims Act and similar provisions in certain state false claims acts allow private individuals

to bring lawsuits against healthcare companies on behalf of government payers, private payers and/or patients alleging inappropriate billing

Although we believe that we are in compliance,

in all material respects, with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not

reach a different conclusion.

The federal or state government may bring claims based on our current practices, which we believe are lawful.

The federal and state governments have substantial leverage in negotiating settlements since the amount of potential damages and fines

far exceeds the rates at which we are reimbursed, and the government has the remedy of excluding a non-compliant provider from participation

in the Medicare and Medicaid programs.

We believe that federal and state governments continue aggressive enforcement efforts against perceived

healthcare fraud.

Legislative provisions relating to healthcare fraud and abuse provide government enforcement personnel with substantial

funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse.

Inflationary pressures could adversely impact

us because of increases in the costs of materials, supplies and services, and increased labor and people-related expenses.

Inflationary pressures have resulted in increases

in the costs of the testing equipment, supplies and other goods and services that we purchase from manufacturers, suppliers and others.

Inflationary pressures, along with the competition for labor, have also resulted in a rise of our labor costs, which include the costs

of compensation, benefits, and recruiting and training new hires.

Our ability to raise the prices and fees we charge for the services

we provide is limited.

Continuation of the current inflationary environment may adversely impact us.

Risk Factors Related to Clinical and Commercialization Activity

We may not be able to file INDs to commence

additional clinical trials on the timelines we expect, and even if we are able to do so, the FDA may not permit us to proceed.

Avalon has initiated its first-in-human clinical

trial of CD19 CAR-T candidate, AVA-001 in August 2019 at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China (the

world’s single largest CAR-T treatment network with over 600 patients being treated with CAR-T) for the indication of relapsed/refractory

B-cell acute lymphoblastic leukemia and non-Hodgkin Lymphoma.

We hope to file a number of investigational new drug applications, or INDs,

for cell based therapies and diagnostic systems through INDs over the next several years.

However, the timing of our filing of these

INDs is primarily dependent on receiving further data from our pre-clinical studies, and our timing of filing on all product candidates

is subject to further research.

Additionally, our submission of INDs is contingent upon having sufficient financial resources to prepare

and complete the application.

We cannot be sure that submission of an IND will

result in the United States Food and Drug Administration, or FDA, allowing further clinical trials to begin, or that, once begun, issues

will not arise that result in the suspension or termination of such clinical trials.

Any IND we submit could be denied by the FDA or

the FDA could place any future investigation of ours on clinical hold until we provide additional information, either before or after

clinical trials are initiated.

Additionally, even if such regulatory authorities agree with the design and implementation of the clinical

trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their

requirements in the future.

Unfavorable future trial results or other factors, such as insufficient capital to continue development of

a product candidate or program, could also cause us to voluntarily withdraw an effective IND.

We have limited experience in conducting clinical

We have limited human clinical trial experience

with respect to our product candidates.

Although our CEO, Dr.

David Jin, is formerly with the FDA, this will not provide assurance of

The clinical testing process is governed by stringent regulation and is highly complex, costly, time-consuming, and uncertain

as to outcome, and pharmaceutical products and products used in the regeneration of tissue may invite particularly close scrutiny and

requirements from the FDA and other regulatory bodies.

Our failure or the failure of our collaborators to conduct human clinical trials

successfully or our failure to capitalize on the results of human clinical trials for our product candidates would have a material adverse

effect on us.

If our clinical trials of our product candidates or future product candidates do not sufficiently enroll or produce results

necessary to support regulatory approval in the United States or elsewhere, or if they show undesirable side effects, we will be unable

to commercialize these product candidates.

To receive regulatory approval for the commercial

sale of our product candidates, we must conduct adequate and well-controlled clinical trials to demonstrate efficacy and safety in humans.

Clinical failure can occur at any stage of the testing.

Our clinical trials may produce negative or inconclusive results, and we may

decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing.

In addition, the results of our clinical

trials may show that our product candidates are ineffective or may cause undesirable side effects, which could interrupt, delay or halt

clinical trials, resulting in the denial of regulatory approval by the FDA and other regulatory authorities.

In addition, negative, delayed

or inconclusive results may result in:

withdrawal of clinical trial participants;

termination of clinical trial sites or entire trial programs;

of related litigation;

● substantial

monetary awards to patients or other claimants;

of our business reputation;

inability to commercialize our product candidates.

Delays in the commencement, enrollment, and

completion of clinical testing could result in increased costs to us and delay or limit our ability to obtain regulatory approval for

our product candidates.

Delays in the commencement, enrollment or completion

of clinical testing could significantly affect our product development costs.

A clinical trial may be suspended or terminated by us,

the FDA, or other regulatory authorities due to a number of factors.

The commencement and completion of clinical trials require us to

identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs for the

same indication as our product candidates.

We may be required to withdraw from a clinical trial as a result of changing standards of

care, or we may become ineligible to participate in clinical studies.

We do not know whether planned clinical trials will begin on time

or be completed on schedule, if at all.

The commencement, enrollment and completion of clinical trials can be delayed for a number of

reasons, including, but not limited to, delays related to:

in pre-clinical studies;

agreements on acceptable terms with prospective clinical research organizations, or CROs,

and trial sites, the terms of which can be subject to extensive negotiation and may vary

significantly among different CROs and trial sites;

regulatory approval to commence a clinical trial;

with conditions imposed by a regulatory authority regarding the scope or term of a clinical

trial, or being required to conduct additional trials before moving on to the next phase

institutional review board, or IRB, approval to conduct a clinical trial at numerous prospective

and enrolling patients to participate in clinical trials for a variety of reasons, including

the size of the patient population, nature of trial protocol, meeting the enrollment criteria

for our studies, screening failures, the inability of the sites to conduct trial procedures

properly, the availability of approved effective treatments for the relevant disease and

competition from other clinical trial programs for similar indications;

patients who have initiated their participation in a clinical trial but may be prone to withdraw

due to the treatment protocol, lack of efficacy, personal issues, or side effects from the

therapy, or who are lost to further follow-up;

● manufacturing

sufficient quantities of a product candidate for use in clinical trials on a timely basis;

with design protocols of any applicable special protocol assessment we receive from the FDA;

or unexpected cell therapy side effects experienced by patients in a clinical trial;

● collecting,

analyzing and reporting final data from the clinical trials;

in quality of manufacturing runs that compromise all or some of the doses made;

results in FDA-required viral testing;

karyotypic abnormalities in our cell product;

or contamination

in our manufacturing facilities, all of which events would necessitate disposal of all cells

made from that source;

● availability

of materials provided by third parties necessary to manufacture our product candidates;

● availability

of adequate amounts of acceptable tissue for preparation of master cell banks for our products;

● requirements

to conduct additional trials and studies, and increased expenses associated with the services

of our CROs and other third parties.

If we are required to conduct additional clinical

trials or other testing of our product candidates beyond those that we currently contemplate, we or our development partners, if any,

may be delayed in obtaining, or may not be able to obtain or maintain, clinical or marketing approval for these product candidates.

may not be able to obtain approval for indications that are as broad as intended, or we may be able to obtain approval only for indications

that are entirely different from those indications for which we sought approval.

Changes in regulatory requirements and guidance

may occur, and we may need to amend clinical trial protocols to reflect these changes with appropriate regulatory authorities.

may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the costs, timing, or successful

completion of a clinical trial.

If we experience delays in the completion of, or if we terminate, our clinical trials, the commercial

prospects for our product candidates will be harmed, and our ability to generate product revenues will be delayed.

In addition, many

of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial

of regulatory approval of a product candidate.

Even if we are able to ultimately commercialize our product candidates, other therapies

for the same or similar indications may have been introduced to the market and already established a competitive advantage.

in obtaining regulatory approvals may:

commercialization of, and our ability to derive product revenues from, our product candidates;

costly procedures on us;

any competitive advantages that we may otherwise enjoy.

Our success depends upon the viability of

our product candidates and we cannot be certain any of them will receive regulatory approval to be commercialized.

We will need FDA approval to market and sell

any of our product candidates in the United States and approvals from FDA-equivalent regulatory authorities in foreign jurisdictions

to commercialize our product candidates in those jurisdictions.

In order to obtain FDA approval of any of our product candidates, we

must submit to the FDA a new drug application, or NDA, or a biologics license application, or BLA, demonstrating that the product candidate

is safe for humans and effective for its intended use.

This demonstration requires significant research and animal tests, which are referred

to as pre-clinical studies, as well as human tests, which are referred to as clinical trials.

Satisfaction of the FDA’s regulatory

requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial

resources for research, development, testing and manufacturing.

We cannot predict whether our research and clinical approaches will result

in cell therapies that the FDA considers safe for humans and effective for indicated uses.

The FDA has substantial discretion in the

drug approval process and may require us to conduct additional pre-clinical and clinical testing or to perform post-marketing studies.

The approval process may also be delayed by changes in government regulation, future legislation, administrative action or changes in

FDA policy that occur prior to or during our regulatory review.

Even if we comply with all FDA requests, the

FDA may ultimately reject one or more of our NDAs or BLAs, as applicable.

We cannot be sure that we will ever obtain regulatory clearance

for our product candidates.

Failure to obtain FDA approval of any of our product candidates will reduce our number of potentially salable

products and, therefore, corresponding product revenues, and will have a material and adverse impact on our business.

As the results of earlier pre-clinical studies

or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have

favorable results in later clinical trials or receive regulatory approval.

Even if our pre-clinical studies and clinical

trials are completed as planned, clinical trials, we cannot be certain that their results will support the claims of our product candidates.

Positive results in pre-clinical testing and early clinical trials do not ensure that results from later clinical trials will also be

positive, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and pre-clinical

A number of companies in the pharmaceutical industry, including those with greater resources and experience, have suffered significant

setbacks in Phase II or Phase III clinical trials, even after seeing promising results in earlier clinical trials.

Our clinical trial process may fail to demonstrate

that our product candidates are safe for humans and effective for indicated uses.

This failure would cause us to abandon a product candidate

and may delay development of other product candidates.

Any delay in, or termination of, our clinical trials will delay or cause us to

refrain from the filing of our NDAs and/or BLAs with the FDA and, ultimately, our ability to commercialize our product candidates and

generate product revenues.

In addition, our clinical trials to date involve small patient populations.

Because of the small sample size,

the results of these clinical trials may not be indicative of future results.

Our business faces significant government

regulation, and there is no guarantee that our product candidates will receive regulatory approval.

Our business faces significant government regulation,

and there is no guarantee that our product candidates will receive regulatory approval.

Our research and development activities, pre-clinical

4 unchanged sentences

Different regulatory requirements may apply to our products depending on how they are categorized by the FDA under these

These regulations can be subject to substantial and significant interpretation, addition, amendment or revision by the FDA and

by the legislative process.

These regulations can be subject to substantial and significant interpretation, addition, amendment or revision by the FDA and by

the legislative process.

The FDA may determine that we will need to undertake clinical trials beyond those currently planned.

6 unchanged sentences

outside of the United States that are subject to regulations established by local authorities and local law.

Any such determinations

would delay or deny the introduction of our product candidates to the market and have a material adverse effect on our business, financial

condition, and results of operations.

Any such determinations would

delay or deny the introduction of our product candidates to the market and have a material adverse effect on our business, financial condition,

and results of operations.

Cell based therapeutics are subject to ongoing

1 unchanged sentence

strict compliance with good manufacturing practices, and other government regulations and corresponding foreign standards.

have control over third-party manufacturers’ compliance with these regulations and standards, nor can we guarantee that we will

maintain compliance with such regulations in regards to our own manufacturing processes.

We do not have

control over third-party manufacturers’ compliance with these regulations and standards, nor can we guarantee that we will maintain

compliance with such regulations in regards to our own manufacturing processes.

Other risks include:

authorities may require the addition of labeling statements, specific warnings, a contraindication,

or field alerts to physicians and pharmacies;

authorities may withdraw their approval of the IND or the product or require us to take our

approved products off the market;

may be required to change the way the product is manufactured or administered and we may

be required to conduct additional clinical trials or change the labeling of our products;

may have limitations on how we promote our products;

may be subject to litigation or product liability claims.

● regulatory authorities may

require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;

● regulatory authorities may

withdraw their approval of the IND or the product or require us to take our approved products off the market;

● we may be required to change

the way the product is manufactured or administered and we may be required to conduct additional clinical trials or change the labeling

of our products;

● we may have limitations on

how we promote our products;

● we may be subject to litigation

or product liability claims.

Even if our product candidates receive regulatory

approval in the United States, we may never receive approval or commercialize our product candidates outside of the United States.

order to market and commercialize any product candidate outside of the United States, we must establish and comply with numerous and

varying regulatory requirements of other countries regarding manufacturing, safety and efficacy.

Approval procedures vary among countries

and can involve additional product testing and additional administrative review periods.

The time required to obtain approval in other

countries might differ from that required to obtain FDA approval.

The regulatory approval process in other countries may include all

of the risks detailed above regarding FDA approval in the United States as well as other risks.

Regulatory approval in one country does

not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative

effect on the regulatory approval process in others.

Failure to obtain regulatory approval in other countries, or any delay or setback

in obtaining such approval, could have the same adverse effects detailed above regarding FDA approval in the United States.

include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product

candidates and have an adverse effect on product sales and potential royalties, and that such approval may be subject to limitations

on the indicated uses for which the product may be marketed or require costly, post-marketing follow-up studies.

order to market and commercialize any product candidate outside of the United States, we must establish and comply with numerous and varying

regulatory requirements of other countries regarding manufacturing, safety and efficacy.

Approval procedures vary among countries and

can involve additional product testing and additional administrative review periods.

The time required to obtain approval in other countries

might differ from that required to obtain FDA approval.

The regulatory approval process in other countries may include all of the risks

detailed above regarding FDA approval in the United States as well as other risks.

Regulatory approval in one country does not ensure

regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the

regulatory approval process in others.

Failure to obtain regulatory approval in other countries, or any delay or setback in obtaining

such approval, could have the same adverse effects detailed above regarding FDA approval in the United States.

Such effects include the

risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates

and have an adverse effect on product sales and potential royalties, and that such approval may be subject to limitations on the indicated

uses for which the product may be marketed or require costly, post-marketing follow-up studies.

Even if our product candidates receive regulatory

3 unchanged sentences

potentially costly post-approval studies.

If any of our products were granted accelerated approval, FDA could require post-marketing

confirmatory trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit.

may withdraw approval of a drug or indication approved under the accelerated approval pathway if a trial required to verify the predicted

clinical benefit of the product fails to verify such benefit;

other evidence demonstrates that the product is not shown to be safe or

effective under the conditions of use;

If any of our products were granted accelerated approval, FDA could require post-marketing confirmatory

trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit.

FDA may withdraw

approval of a drug or indication approved under the accelerated approval pathway if a trial required to verify the predicted clinical

benefit of the product fails to verify such benefit;

other evidence demonstrates that the product is not shown to be safe or effective

under the conditions of use;

the applicant fails to conduct any required post-approval trial of the drug with due diligence;

or the applicant disseminates false or misleading promotional materials relating to the product.

In addition, the FDA currently requires

as a condition for accelerated approval the pre-approval of promotional materials, which could adversely impact the timing of the commercial

launch of the product.

or the applicant

disseminates false or misleading promotional materials relating to the product.

In addition, the FDA currently requires as a condition

for accelerated approval the pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of

Given the number of recent high-profile adverse

7 unchanged sentences

restrictions or requirements could force us to conduct costly studies or increase the time for us to become profitable.

any labeling approved for any of our product candidates may include a restriction on the term of its use, or it may not include one or

more of our intended indications.

For example, any

labeling approved for any of our product candidates may include a restriction on the term of its use, or it may not include one or more

of our intended indications.

Our product candidates will also be subject to

7 unchanged sentences

restrictions on that product or us, including requiring withdrawal of the product from the market or for use in a clinical study.

our product candidates fail to comply with applicable regulatory requirements, such as good manufacturing practices, a regulatory agency

warning letters;

us to enter into a consent decree, which can include imposition of various fines, reimbursements

for inspection costs, required due dates for specific actions, and penalties for noncompliance;

other civil or criminal penalties;

regulatory approval;

any ongoing clinical trials;

to approve pending applications or supplements to approved applications filed by us;

restrictions on operations, including costly new manufacturing requirements;

or detain products or require a product recall.

If we or current or future collaborators,

manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions

and substantial penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.

product candidates fail to comply with applicable regulatory requirements, such as good manufacturing practices, a regulatory agency may:

● issue warning letters;

● require us to enter into a

consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions,

and penalties for noncompliance;

● impose other civil or criminal

● suspend regulatory approval;

● suspend any ongoing clinical

● refuse to approve pending applications

or supplements to approved applications filed by us;

● impose restrictions on operations,

including costly new manufacturing requirements;

● seize or detain products or

require a product recall.

If we or current or future collaborators, manufacturers,

or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and substantial

penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.

Although we do not currently have any products

on the market, once our therapeutic candidates or clinical trials are covered by federal health care programs, we will be subject to

additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions

in which we conduct our business.

Healthcare providers, physicians and third party payors play a primary role in the recommendation and

prescription of any therapeutic candidates for which we obtain marketing approval.

Our future arrangements with third party payors and

customers may expose us to broadly applicable fraud and abuse, transparency, and other healthcare laws and regulations that may constrain

the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for

which we obtain marketing approval.

Restrictions under applicable federal and state healthcare laws and regulations include, but are

not limited to, the following:

federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting,

receiving, offering or providing remuneration, directly or indirectly, to induce either the

referral of an individual for a healthcare item or service, or the purchasing or ordering

of an item or service, for which payment may be made, in whole or in part, under a federal

healthcare program such as Medicare or Medicaid;

civil and criminal false claims laws and civil monetary penalty laws, such as the U.S.

FCA, which imposes criminal and civil penalties, including through civil whistleblower or

qui tam actions, against, individuals or entities for knowingly presenting or causing to

be presented, to the federal government, claims for payment that are false or fraudulent

or making a false statement to avoid, decrease or conceal an obligation to pay money to the

federal government.

In addition, the government may assert that a claim including items and

services resulting from a violation of the federal Anti-Kickback Statute constitutes a false

or fraudulent claim for purposes of the FCA;

includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which

imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit

program, or knowingly and willfully falsifying, concealing or covering up a material fact

or making any materially false statement in connection with the delivery of or payment for

healthcare benefits, items or services.

Similar to the federal Anti-Kickback Statute, a person

or entity does not need to have actual knowledge of the statute or specific intent to violate

it in order to have committed a violation;

as amended by HITECH, and its implementing regulations, which impose obligations on certain

covered entity healthcare providers, health plans, and healthcare clearinghouses as well

as their business associates that perform certain services involving the use or disclosure

of individually identifiable health information, including mandatory contractual terms, with

respect to safeguarding, the privacy, security, and transmission of individually identifiable

health information, and require notification to affected individuals and regulatory authorities

of certain breaches of security of individually identifiable health information;

and state consumer protection and unfair competition laws, which broadly regulate marketplace

activities and activities that potentially harm consumers;

federal Physician Payment Sunshine Act and the implementing regulations, also referred to

as “Open Payments,” issued under the ACA, which require that manufacturers of

pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children’s

Health Insurance Programs report to the Department of Health and Human Services all consulting

fees, travel reimbursements, research grants, and other payments, transfers of value or gifts

made to physicians and teaching hospitals with limited exceptions;

state laws and regulations, such as, state anti-kickback and false claims laws potentially

applicable to sales or marketing arrangements and claims involving healthcare items or services

reimbursed by nongovernmental third party payors, including private insurers;

and some state

laws require pharmaceutical companies to comply with the pharmaceutical industry’s

voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal

government in addition to requiring drug and cell based therapy manufacturers to report information

related to payments to physicians and other healthcare providers or marketing expenditures,

and state laws governing the privacy and security of health information in certain circumstances,

many of which differ from each other in significant ways and often are not preempted by HIPAA,

thus complicating compliance efforts.

on the market, once our therapeutic candidates or clinical trials are covered by federal health care programs, we will be subject to additional

healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in

which we conduct our business.

Healthcare providers, physicians and third party payors play a primary role in the recommendation and prescription

of any therapeutic candidates for which we obtain marketing approval.

Our future arrangements with third party payors and customers may

expose us to broadly applicable fraud and abuse, transparency, and other healthcare laws and regulations that may constrain the business

or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain

marketing approval.

Restrictions under applicable federal and state healthcare laws and regulations include, but are not limited to, the

federal Anti-Kickback

Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly,

to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service,

for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;

● federal civil and criminal

false claims laws and civil monetary penalty laws, such as the U.S.

federal FCA, which imposes criminal and civil penalties, including

through civil whistleblower or qui tam actions, against, individuals or entities for knowingly presenting or causing to be presented,

to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal

an obligation to pay money to the federal government.

In addition, the government may assert that a claim including items and services

resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;

● HIPAA includes a fraud and

abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud

any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially

false statement in connection with the delivery of or payment for healthcare benefits, items or services.

Similar to the federal Anti-Kickback

Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed

● HIPAA, as amended by HITECH,

and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare

clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable

health information, including mandatory contractual terms, with respect to safeguarding, the privacy, security, and transmission of individually

identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security

of individually identifiable health information;

● federal and state consumer

protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

● the federal Physician Payment

Sunshine Act and the implementing regulations, also referred to as “Open Payments,” issued under the ACA, which require that

manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children’s Health Insurance Programs

report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments,

transfers of value or gifts made to physicians and teaching hospitals with limited exceptions;

● analogous state laws and regulations,

such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare

items or services reimbursed by nongovernmental third party payors, including private insurers;

and some state laws require pharmaceutical

companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated

by the federal government in addition to requiring drug and cell based therapy manufacturers to report information related to payments

to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information

in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating

compliance efforts.

The scope and enforcement of each of these laws

5 unchanged sentences

Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

Ensuring that our business arrangements with

third-parties comply with applicable healthcare laws and regulations could involve substantial costs.

If our operations are found to

be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the

curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or

other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results.

Although effective

compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely

Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could

divert our management’s attention from the operation of our business, even if our defense is successful.

In addition, achieving

and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.

Ensuring that our business arrangements with third-parties

comply with applicable healthcare laws and regulations could involve substantial costs.

If our operations are found to be in violation

of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or

restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government

programs, including Medicare and Medicaid, any of which could adversely affect our financial results.

Although effective compliance programs

can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated.

against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s

attention from the operation of our business, even if our defense is successful.

In addition, achieving and sustaining compliance with

applicable laws and regulations may be costly to us in terms of money, time and resources.

Any cell based therapies we develop may become

11 unchanged sentences

stages of development and we will not be able to assess the impact of price regulations for a number of years.

As a result, we might

obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial

launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.

As a result, we might obtain

regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of

the product and negatively impact the revenues we are able to generate from the sale of the product in that country.

Our ability to commercialize any products successfully

6 unchanged sentences

sale and distribution costs.

Also, interim payments for new cell based therapy if applicable, may be insufficient to cover our costs

and may not be made permanent.

Also, interim payments for new cell based therapy if applicable, may be insufficient to cover our costs and

may not be made permanent.

Thus, even if we succeed in bringing one or more products to the market, these products may not be considered

9 unchanged sentences

reimbursement rate will be approved.

Further, one payor’s determination to provide coverage for a product does not assure that

other payors will also provide coverage for the product.

Adequate third-party reimbursement may not be available to enable us to maintain

price levels sufficient to realize an appropriate return on our investment in product development.

If reimbursement is not available

or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.

Further, one payor’s determination to provide coverage for a product does not assure that other

payors will also provide coverage for the product.

Adequate third-party reimbursement may not be available to enable us to maintain price

levels sufficient to realize an appropriate return on our investment in product development.

If reimbursement is not available or is available

only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.

Increasingly, the third party payors who reimburse

2 unchanged sentences

If the price we are able to charge for any products we develop,

or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment

could be adversely affected.

or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could

be adversely affected.

We currently expect that certain drugs we develop

1 unchanged sentence

Under currently applicable U.S.

drugs that are not usually self-administered (including injectable cell based therapies) may be eligible for coverage under Medicare

through Medicare Part B.

Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among

other requirements have been satisfied:

product is reasonable and necessary for the diagnosis or treatment of the illness or injury

for which the product is administered according to accepted standards of medical practice;

product is typically furnished incident to a physician’s services;

indication for which the product will be used is included or approved for inclusion in certain

Medicare-designated pharmaceutical compendia (when used for an off-label use);

product has been approved by the FDA.

drugs that are not usually self-administered (including injectable cell based therapies) may be eligible for coverage under Medicare through

Medicare Part B.

Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements

have been satisfied:

● the product is reasonable and

necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards

of medical practice;

● the product is typically furnished

incident to a physician’s services;

● the indication for which the

product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an

off-label use);

● the product has been approved

Average prices for cell therapies may be reduced

9 unchanged sentences

federal healthcare programs are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints placed on

the Medicare program.

Medicare reimbursement rates may also reflect budgetary constraints placed on the

Medicare program.

Third party payors often rely upon Medicare coverage

7 unchanged sentences

We expect that these and other healthcare reform

measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional

downward pressure on the price that we receive for any approved product.

measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward

pressure on the price that we receive for any approved product.

Any reduction in reimbursement from Medicare or other government-funded

programs may result in a similar reduction in payments from private payors.

The implementation of cost containment measures or other

healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our cell based therapies,

once marketing approval is obtained.

The implementation of cost containment measures or other healthcare

reforms may prevent us from being able to generate revenue, attain profitability or commercialize our cell based therapies, once marketing

approval is obtained.

We believe that the efforts of governments and

13 unchanged sentences

products, of importance to our potential therapeutic candidates are the following:

to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due

to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and

the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed

expansion of the 340B Drug Pricing Program to require discounts for “covered outpatient

drugs” sold to certain children’s hospitals, critical access hospitals, freestanding

cancer hospitals, rural referral centers, and sole community hospitals;

● requirements

imposed on pharmaceutical companies are required to offer discounts on brand-name cell based

therapy to patients who fall within the Medicare Part D coverage gap, commonly referred to

as the “Donut Hole”;

● requirements

imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal

government based on each company’s market share of prior year total sales of branded

drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans

Affairs and Department of Defense;

products classified as biologics, marketing approval for a follow-on biologic product may

not become effective until 12 years after the date on which the reference innovator biologic

product was first licensed by the FDA, with a possible six-month extension for pediatric

After this exclusivity ends, it may be possible for biosimilar manufacturers to

enter the market, which is likely to reduce the pricing for the innovator product and could

affect our profitability if our products are classified as biologics.

● increases to pharmaceutical

manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most

branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans;

● the expansion of the 340B Drug

Pricing Program to require discounts for “covered outpatient drugs” sold to certain children’s hospitals, critical

access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals;

● requirements imposed on pharmaceutical

companies are required to offer discounts on brand-name cell based therapy to patients who fall within the Medicare Part D coverage gap,

commonly referred to as the “Donut Hole”;

● requirements imposed on pharmaceutical

companies to pay an annual non-tax-deductible fee to the federal government based on each company’s market share of prior year

total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department

● for products classified as

biologics, marketing approval for a follow-on biologic product may not become effective until 12 years after the date on which the reference

innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products.

After this exclusivity

ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for the innovator product

and could affect our profitability if our products are classified as biologics.

Separately, pursuant to the health reform legislation

11 unchanged sentences

FDA approval for any of its products in the future.

For example, if we receive FDA approval for a product for which reimbursement is

available under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations,

including those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g.

the federal False

Claims Act), prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g.

Anti-Kickback Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching

hospitals or Open Payments.

We are not able to predict how third parties will interpret these laws and apply applicable governmental

guidance and may challenge our practices and activities under one or more of these laws.

If our past or present operations are found

to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations

and financial condition.

The federal Anti-Kickback Statute prohibits,

among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly

For example, if we receive FDA approval for a product for which reimbursement is available

under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including

those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g.

the federal False Claims Act),

prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g.

the federal Anti-Kickback

Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals

or Open Payments.

We are not able to predict how third parties will interpret these laws and apply applicable governmental guidance and

may challenge our practices and activities under one or more of these laws.

If our past or present operations are found to be in violation

of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial

The federal Anti-Kickback Statute prohibits, among

other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly

or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the

purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs.

remuneration has been interpreted broadly to include anything of value.

The Anti-Kickback Statute has been interpreted to apply to arrangements

between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other.

There are a number

of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.

The exceptions and safe harbors

are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending

may be subject to scrutiny if they do not qualify for an exception or safe harbor.

Failure to meet all of the requirements of a particular

applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute.

the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.

Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

The term remuneration

has been interpreted broadly to include anything of value.

The Anti-Kickback Statute has been interpreted to apply to arrangements between

pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other.

There are a number of statutory

exceptions and regulatory safe harbors protecting some common activities from prosecution.

The exceptions and safe harbors are drawn narrowly

and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject

to scrutiny if they do not qualify for an exception or safe harbor.

Failure to meet all of the requirements of a particular applicable

statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute.

Instead, the legality

of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.

Our practices

may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent standard under the Anti-Kickback

4 unchanged sentences

of the federal FCA.

The civil monetary penalties statute imposes

penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to

a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false

or fraudulent.

The civil monetary penalties statute imposes penalties

against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal

healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.

Federal false claims and false statement laws,

including the federal FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented,

a false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly

including the federal FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a

false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly

making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government.

12 unchanged sentences

the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security

of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers

with respect to such information.

Additionally, many states have enacted similar laws that may impose more stringent requirements on

entities like ours.

Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect

our financial condition and results of operations.

of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with

respect to such information.

Additionally, many states have enacted similar laws that may impose more stringent requirements on entities

Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial

condition and results of operations.

Many states also have similar fraud and abuse

2 unchanged sentences

Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign

Our products, once approved, may be eligible

for coverage under Medicare and Medicaid, among other government healthcare programs.

Our products, once approved, may be eligible for

coverage under Medicare and Medicaid, among other government healthcare programs.

Accordingly, we may be subject to a number of obligations

based on their participation in these programs, such as a requirement to calculate and report certain price reporting metrics to the

government, such as average sales price (ASP) and best price.

Penalties may apply in some cases when such metrics are not submitted accurately

Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs

or private payors and by any future relaxation of laws that presently restrict imports of drugs and biological products from countries

where they may be sold at lower prices than in the United States.

It is difficult to predict how Medicare coverage and reimbursement

policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs are

not always consistent.

based on their participation in these programs, such as a requirement to calculate and report certain price reporting metrics to the government,

such as average sales price (ASP) and best price.

Penalties may apply in some cases when such metrics are not submitted accurately and

Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or

private payors and by any future relaxation of laws that presently restrict imports of drugs and biological products from countries where

they may be sold at lower prices than in the United States.

It is difficult to predict how Medicare coverage and reimbursement policies

will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs are not always

Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.

1 unchanged sentence

we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products

in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers

or distributors have no place of business within the state.

Some states also impose requirements on manufacturers and distributors to

establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt

new technology capable of tracking and tracing product as it moves through the distribution chain.

Several states have enacted legislation

requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state,

make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives,

as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and

biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices.

All of our activities

are potentially subject to federal and state consumer protection and unfair competition laws.

in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or

distributors have no place of business within the state.

Some states also impose requirements on manufacturers and distributors to establish

the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology

capable of tracking and tracing product as it moves through the distribution chain.

Several states have enacted legislation requiring

pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic

public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as

well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology

companies for use in sales and marketing, and to prohibit certain other sales and marketing practices.

All of our activities are potentially

subject to federal and state consumer protection and unfair competition laws.

If our operations are found to be in violation

of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject

to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion

from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought

by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages,

reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations,

any of which could adversely affect our ability to operate our business and our results of operations.

to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from

participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by individual

whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational

harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which

could adversely affect our ability to operate our business and our results of operations.

Our ability to obtain reimbursement or funding

17 unchanged sentences

could, among other things, cut Medicare payments to providers.

The Medicare program is frequently mentioned as a target for spending

The Medicare program is frequently mentioned as a target for spending cuts.

The full impact on our business of any future cuts in Medicare or other programs is uncertain.

In addition, we cannot predict any

impact President Trump’s administration and the U.S.

In addition, we cannot predict any impact

President Trump’s administration and the U.S.

Congress may have on the federal budget.

16 unchanged sentences

transactions.

This concentration of ownership could delay or prevent any acquisition of our company on terms that other stockholders

may desire, and may adversely affect the market price of our common stock.

This concentration of ownership could delay or prevent any acquisition of our company on terms that other stockholders may

desire, and may adversely affect the market price of our common stock.

If we are unable to maintain listing of our

2 unchanged sentences

certain standards in order to remain listed on its exchange.

If, for any reason, Nasdaq should delist our securities from trading on

its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the

following may occur, each of which could materially adversely affect our stockholders.

A delisting of our common stock is likely to reduce

the liquidity of our common stock and may inhibit or preclude our ability to raise additional financing.

On February 9, 2022, the Company received notice from

The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for the Company’s common stock had been below $1.00 per

share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement

for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

Nasdaq’s notice

had no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market.

The notice indicated

that the Company will have 180 calendar days, until August 8, 2022, to regain compliance with the Rule.

On August 9, 2022, we were provided

an additional compliance period of 180 calendar days, or until February 6, 2023, to regain compliance with the minimum closing bid requirement.

The Company could regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of its common stock is at

least $1.00 per share for a minimum of ten (10) consecutive business days during the 180-day compliance period.

If the Company did not

regain compliance during the initial compliance period, it may be eligible for additional time to regain compliance with the Rule.

qualify, the Company was required to meet the continued listing requirement for market value of its publicly held shares and all other

Nasdaq initial listing standards, except the bid price requirement, and provide written notice to Nasdaq of its intention to cure the

deficiency during the second compliance period by effecting a reverse stock split, if necessary.

If the Company was not eligible or it

appeared to Nasdaq that the Company was not be able to cure the deficiency during the second compliance period, Nasdaq then provides written

notice to the Company that the Company’s common stock will be subject to delisting.

In the event of such notification, the Company

may appeal Nasdaq’s determination to delist its securities, but there can be no assurance that Nasdaq would grant the Company’s

request for continued listing.

We effected a one-for-ten reverse stock split on January 5, 2023.

On January 20, 2023, we received a letter

from the staff of Nasdaq indicating that we have regained compliance with the Rule and as of the date of this filing, this matter is now

If, for any reason, Nasdaq should delist our securities from trading on its

exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following

may occur, each of which could materially adversely affect our stockholders.

A delisting of our common stock is likely to reduce the liquidity

of our common stock and may inhibit or preclude our ability to raise additional financing.

On November 3, 2023, we received notice

from Nasdaq that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive

business days, and that we were therefore not in compliance with the minimum bid price requirement for continued inclusion on

The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

Nasdaq’s notice had no immediate effect

on the listing or trading of our common stock on The Nasdaq Capital Market.

The notice indicated that we will

have 180 calendar days, until May 1, 2024, to regain compliance with the Rule.

We could regain compliance with the $1.00 minimum

bid listing requirement if the closing bid price of our common stock is at least $1.00 per share for a minimum of ten (10) consecutive

business days during the 180-day compliance period.

If we do not regain compliance during the initial compliance period, we

may be eligible for additional time to regain compliance with the Rule.

To qualify, we will be required to meet the continued

listing requirement for market value of our publicly held shares and all other Nasdaq initial listing standards, except the bid price

requirement, and provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period by effecting

a reverse stock split, if necessary.

If we are not eligible or it appeared to Nasdaq that we will not be able to cure

the deficiency during the second compliance period, Nasdaq then provides written notice to us that our common

stock will be subject to delisting.

In the event of such notification, we may appeal Nasdaq’s determination to delist our

securities, but there can be no assurance that Nasdaq will grant our request for continued listing.

The price of our common stock may be volatile and fluctuate substantially,

which could result in substantial losses for our stockholders.

Our common stock has

been listed on the Nasdaq Capital Market under the symbol “ALBT” since November 10, 2022.

Our common stock was listed on the

Nasdaq Capital Market under the symbol “AVCO” since November 5, 2018 through the close of business on November 9, 2022.

common shares were traded previously on the OTC Market Group Inc.’s Venture Market (the “OTCQB”) since February 22,

2016, under the symbol “AVCO” since October 18, 2016 and “GTHC” prior to October 18, 2016.

Our common stock has been listed on the Nasdaq

Capital Market under the symbol “ALBT” since November 10, 2022.

Our common stock was listed on the Nasdaq Capital Market under

the symbol “AVCO” since November 5, 2018 through the close of business on November 9, 2022.

Our common shares were traded

previously on the OTC Market Group Inc.’s Venture Market (the “OTCQB”) since February 22, 2016, under the symbol “AVCO”

since October 18, 2016 and “GTHC” prior to October 18, 2016.

The price of our common stock has been, and we

5 unchanged sentences

market price for our common stock may be influenced by many factors, including:

● the success of competitive products or technologies;

● developments related to our existing or any future

collaborations;

● regulatory or legal developments in the United

States and other countries;

● developments or disputes concerning patent applications,

issued patents or other proprietary rights;

● the recruitment or departure of key personnel;

● actual or anticipated changes in estimates as

to financial results or recommendations by securities analysts;

● variations in our financial results or those

of companies that are perceived to be similar to us;

● changes in the structure of healthcare payment

● market conditions in the healthcare, pharmaceutical

and biotechnology sectors;

● general economic, industry and market conditions;

● the other factors described in this “Risk

Factors” section.

Future sales of our common stock or securities

convertible or exchangeable for our common stock may cause our stock price to decline.

If our existing stockholders sell, or indicate

an intention to sell, substantial amounts of our common stock in the public market, the price of our common stock could decline.

The perception

in the market that these sales may occur could also cause the price of our common stock to decline.

In addition, as of December 31, 2022, 924,464

shares of common stock issuable upon exercise of outstanding stock options and warrants and 900,000 shares of common stock issuable upon

conversion of outstanding Series A convertible preferred stock, which will become eligible for sale in the public market to the extent

permitted by the provisions of various vesting schedules, the lock-up agreements and Rule 144 under the Securities Act.

If the shares

we may issue from time to time upon exercise of outstanding options and warrants and conversion of outstanding Series A convertible preferred

stock are sold, or if it is perceived that they will be sold, by the award recipients in the public market, the price of our common stock

could decline.

● the success of competitive

products or technologies;

● developments related to our

existing or any future collaborations;

● regulatory or legal developments

in the United States and other countries;

● developments or disputes concerning

patent applications, issued patents or other proprietary rights;

● the recruitment or departure

of key personnel;

● actual or anticipated changes

in estimates as to financial results or recommendations by securities analysts;

● variations in our financial

results or those of companies that are perceived to be similar to us;

● changes in the structure of

healthcare payment systems;

● market conditions in the healthcare,

pharmaceutical and biotechnology sectors;

● general economic, industry

and market conditions;

● the other factors described

in this “Risk Factors” section.

sales of our common stock or securities convertible or exchangeable for our common stock may cause our stock price to decline.

our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the price

of our common stock could decline.

The perception in the market that these sales may occur could also cause the price of our common stock

addition, as of December 31, 2023,

shares of our common stock were issuable upon exercise of outstanding stock options;

shares of our common stock were issuable upon exercise of outstanding stock warrants;

shares of our common stock were issuable upon the conversion of our outstanding Series A

Convertible Preferred Stock (the “Series A Preferred Stock”), which will become

eligible for sale in the public market to the extent permitted by the provisions of various

vesting schedules, lock-up agreements and Rule 144 under the Securities Act of 1933, as amended

(the “Securities Act”);

shares of our common stock issuable upon conversion of our outstanding Series B Preferred

shares of our common stock issuable upon conversion of our outstanding convertible notes.

the shares we may issue from time to time upon the exercise of outstanding options and warrants and the conversion of our outstanding

Series A Preferred Stock and Series B Preferred Stock are sold and outstanding convertible notes are issues, or if it is perceived that

they will be sold, by the award recipients in the public market, the price of our common stock could decline.

You may experience dilution of your ownership

2 unchanged sentences

As of the date of this filing, we have issued

an aggregate of (i) 9,000 shares of our newly designated Series A Convertible Preferred Stock and (ii) 11,000 shares of our newly designated

Series B Convertible Preferred Stock.

In the future, we may issue our authorized but previously unissued equity securities, resulting

in the dilution of the ownership interests of our stockholders.

We are authorized to issue an aggregate of 490,000,000 shares of common

stock and 10,000,000 shares of “blank check” preferred stock.

We may issue additional shares of our common stock or other

securities that are convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions,

future sales of our securities for capital raising purposes, or for other business purposes.

The future issuance of any such additional

shares of our common stock may create downward pressure on the trading price of the common stock.

We expect we will need to raise additional

capital in the near future to meet our working capital needs, and there can be no assurance that we will not be required to issue additional

shares, warrants or other convertible securities in the future in conjunction with these capital raising efforts, including at a price

(or exercise prices) below the price you paid for your stock.

The ability of our Board of Directors to issue

additional stock may prevent or make more difficult certain transactions, including a sale or merger.

Our Board of Directors is authorized to issue

up to 10,000,000 shares of preferred stock with powers, rights and preferences designated by it.

Shares of voting or convertible preferred

stock could be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons seeking

to effect a takeover or otherwise gain control of us.

The rights of holders of our common stock are subject to the rights of the holders

of our preferred stock, including our newly designated Series A Convertible Preferred Stock and Series B Convertible Preferred Stock,

and any preferred stock that may be issued.

The ability of the Board of Directors to issue such additional shares of preferred stock,

with rights and preferences it deems advisable, could discourage an attempt by a party to acquire control of us by tender offer or other

Such issuances could therefore deprive stockholders of benefits that could result from such an attempt, such as the realization

of a premium over the market price for their shares in a tender offer or the temporary increase in market price that such an attempt could

Moreover, the issuance of such additional shares of preferred stock to persons friendly to the Board of Directors could make it

more difficult to remove incumbent managers and directors from office even if such change were to be favorable to stockholders generally.

an aggregate of (i) 9,000 shares of our newly designated Series A Preferred Stock and (ii) 11,000 shares of our newly designated Series

B Preferred Stock.

In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of

the ownership interests of our stockholders.

We are authorized to issue an aggregate of 490,000,000 shares of common stock and 10,000,000

shares of “blank check” preferred stock.

We may issue additional shares of our common stock or other securities that are convertible

into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities

for capital raising purposes, or for other business purposes.

The future issuance of any such additional shares of our common stock may

create downward pressure on the trading price of our common stock.

We expect we will need to raise additional capital in the near future

to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or

other convertible securities in the future in conjunction with these capital raising efforts, including at a price (or exercise prices)

below the price you paid for your stock.

The ability of our Board to issue additional

stock may prevent or make more difficult certain transactions, including a sale or merger.

Our Board is authorized to issue up to 10,000,000

shares of preferred stock with powers, rights and preferences designated by it.

Shares of voting or convertible preferred stock could

be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons seeking to effect a

takeover or otherwise gain control of us.

The rights of holders of our common stock are subject to the rights of the holders of our preferred

stock, including our newly designated Series A Preferred Stock, Series B Preferred Stock, Series C Convertible Preferred Stock and any

preferred stock that may be issued.

The ability of the Board to issue such additional shares of preferred stock, with rights and preferences

it deems advisable, could discourage an attempt by a party to acquire control of us by tender offer or other means.

Such issuances could

therefore deprive stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market

price for their shares in a tender offer or the temporary increase in market price that such an attempt could cause.

Moreover, the issuance

of such additional shares of preferred stock to persons friendly to the Board could make it more difficult to remove incumbent managers

and directors from office even if such change were to be favorable to stockholders generally.

We are incorporated in Delaware.

4 unchanged sentences

with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities,

our Board of Directors approves the transaction.

Our Board of Directors may use these provisions to prevent changes in the management

and control of us.

Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.

our Board approves the transaction.

Our Board may use these provisions to prevent changes in the management and control of us.

applicable Delaware law, our Board may adopt additional anti-takeover measures in the future.

If securities or industry analysts do not publish

16 unchanged sentences

on our common stock, and we do not anticipate such a declaration or payment for the foreseeable future.

We expect to use future earnings, if any, to fund

business growth.

Therefore, stockholders will not receive any funds absent a sale of their shares of common stock.

We cannot assure stockholders

of a positive return on their investment when they sell their shares, nor can we assure that stockholders will not lose the entire amount

of their investment.

We expect to use

future earnings, if any, to fund business growth.

Therefore, stockholders will not receive any funds absent a sale of their shares

of our common stock.

We cannot assure stockholders of a positive return on their investment when they sell their shares, nor can we

assure that stockholders will not lose the entire amount of their investment.

Applicable regulatory requirements, including

31 unchanged sentences

the applicable trading market we could face significant consequences, including.

● a limited availability for market quotations

for our securities;

● reduced liquidity with respect to our securities;

● a determination that our common stock is a “penny

stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced

level of trading activity in the secondary trading market for our common stock;

● limited amount of news and analyst coverage;

● a decreased ability to issue additional securities

or obtain additional financing in the future.

● a limited availability for

market quotations for our securities;

● reduced liquidity with respect

to our securities;

● a determination that our common

stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly

result in a reduced level of trading activity in the secondary trading market for our common stock;

● limited amount of news and

analyst coverage;

● a decreased ability to issue

additional securities or obtain additional financing in the future.

We could be subject to securities class action

5 unchanged sentences

it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

UNRESOLVED STAFF COMMENTS

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors